BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978. [PMID: 20209604 DOI: 10.1002/hep.23527] [Cited by in Crossref: 759] [Cited by in F6Publishing: 705] [Article Influence: 69.0] [Reference Citation Analysis]
Number Citing Articles
1 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
2 Shrager B, Jibara GA, Tabrizian P, Roayaie S, Ward SC. Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int J Surg Oncol. 2012;2012:915128. [PMID: 22988496 DOI: 10.1155/2012/915128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Neeland IJ, Yokoo T, Leinhard OD, Lavie CJ. 21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient. JACC Cardiovasc Imaging 2021;14:482-94. [PMID: 32305476 DOI: 10.1016/j.jcmg.2020.02.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
4 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 114.4] [Reference Citation Analysis]
5 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 471] [Article Influence: 63.3] [Reference Citation Analysis]
6 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
7 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015;9:603-27. [DOI: 10.1586/17474124.2015.1007955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 11.7] [Reference Citation Analysis]
9 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
10 Esteban-Zubero E, García-Gil FA, López-Pingarrón L, Alatorre-Jiménez MA, Ramírez JM, Tan DX, García JJ, Reiter RJ. Melatonin role preventing steatohepatitis and improving liver transplantation results. Cell Mol Life Sci 2016;73:2911-27. [PMID: 27022943 DOI: 10.1007/s00018-016-2185-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl 2018;24:1171-7. [PMID: 29781162 DOI: 10.1002/lt.25202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
12 Zhai M, Liu Z, Long J, Zhou Q, Yang L, Zhou Q, Liu S, Dai Y. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep 2021;11:5195. [PMID: 33664363 DOI: 10.1038/s41598-021-84577-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Hyun J, Jung Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8138. [PMID: 33143364 DOI: 10.3390/ijms21218138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
14 Plentz RR, Malek NP. Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline? Diagnostics (Basel) 2015;5:497-503. [PMID: 26854167 DOI: 10.3390/diagnostics5040497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 16.7] [Reference Citation Analysis]
16 He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:9729107. [PMID: 28326329 DOI: 10.1155/2017/9729107] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
17 Fingas CD, Best J, Sowa J-P, Canbay A. Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clinical Liver Disease. 2016;8:119-122. [PMID: 31041078 DOI: 10.1002/cld.585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
18 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
19 Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 2012;42:767-773. [PMID: 22487102 DOI: 10.1111/j.1872-034x.2012.00986.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
20 Chen QR, Braun R, Hu Y, Yan C, Brunt EM, Meerzaman D, Sanyal AJ, Buetow K. Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One. 2013;8:e65982. [PMID: 23894275 DOI: 10.1371/journal.pone.0065982] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
21 Shen J, Wong GL, Chan HL, Chan RS, Chan H, Chu WC, Cheung BH, Yeung DK, Li LS, Sea MM, Woo J, Wong VW. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease: PNPLA3 and lifestyle modification. J Gastroenterol Hepatol 2015;30:139-46. [DOI: 10.1111/jgh.12656] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
22 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
23 Palmer M. Nonalcoholic Fatty Liver Disease. In: Mullin GE, Cheskin LJ, Matarese LE, editors. Integrative Weight Management. New York: Springer; 2014. pp. 145-69. [DOI: 10.1007/978-1-4939-0548-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med 2017;5:161. [PMID: 28480197 DOI: 10.21037/atm.2017.03.107] [Cited by in Crossref: 246] [Cited by in F6Publishing: 218] [Article Influence: 61.5] [Reference Citation Analysis]
25 Honda T, Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Clinical characteristics of hepatocellular carcinoma in elderly patients. Oncol Lett 2011;2:851-4. [PMID: 22866139 DOI: 10.3892/ol.2011.359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 923] [Article Influence: 168.3] [Reference Citation Analysis]
27 Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 2012;87:9-16. [PMID: 22212963 DOI: 10.1016/j.mayocp.2011.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
28 Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019;21:285-92. [DOI: 10.1111/dom.13520] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 35.3] [Reference Citation Analysis]
29 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155. [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034] [Cited by in Crossref: 526] [Cited by in F6Publishing: 482] [Article Influence: 75.1] [Reference Citation Analysis]
30 Sanyal AJ. NASH: A global health problem: NASH: A global health problem. Hepatology Research 2011;41:670-4. [DOI: 10.1111/j.1872-034x.2011.00824.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 53] [Article Influence: 9.9] [Reference Citation Analysis]
31 Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. J Diabetes Complications 2021;35:107885. [PMID: 33602617 DOI: 10.1016/j.jdiacomp.2021.107885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141-152. [PMID: 23430399 DOI: 10.1007/s00795-013-0016-1] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 20.8] [Reference Citation Analysis]
33 Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G. Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink? Nutrients 2019;11:E3048. [PMID: 31847199 DOI: 10.3390/nu11123048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
34 Romualdo GR, Da Silva TC, de Albuquerque Landi MF, Morais JÁ, Barbisan LF, Vinken M, Oliveira CP, Cogliati B. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. Environ Toxicol 2021;36:168-76. [PMID: 32918399 DOI: 10.1002/tox.23021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Serra MP, Doratiotto S, Marongiu F, Laconi E. Normal hepatocyte transplantation delays the emergence of chemically induced preneoplastic nodules in rat liver. Cell Transplant 2012;21:671-7. [PMID: 21944459 DOI: 10.3727/096368911X600975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, Perola M, Färkkilä M, Jula A. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population Cohorts. Hepatology 2020;71:835-48. [DOI: 10.1002/hep.30864] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
37 Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(19): 3407-3417 [PMID: 28596677 DOI: 10.3748/wjg.v23.i19.3407] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
39 Maehara N, Arai S, Mori M, Iwamura Y, Kurokawa J, Kai T, Kusunoki S, Taniguchi K, Ikeda K, Ohara O, Yamamura KI, Miyazaki T. Circulating AIM prevents hepatocellular carcinoma through complement activation. Cell Rep. 2014;9:61-74. [PMID: 25284781 DOI: 10.1016/j.celrep.2014.08.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
40 Leitão J, Carvalhana S, Cochicho J, Silva AP, Velasco F, Medeiros I, Alves AC, Bourbon M, Oliveiros B, Rodrigues V, Sousa R, Sampaio F, Carvalho A, Cortez-Pinto H. Prevalence and risk factors of fatty liver in Portuguese adults.Eur J Clin Invest. 2020;50:e13235. [PMID: 32289180 DOI: 10.1111/eci.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
42 Hiwatashi K, Ueno S, Sakoda M, Iino S, Minami K, Yamasaki Y, Okubo K, Noda M, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. J Cancer 2015;6:438-47. [PMID: 25874007 DOI: 10.7150/jca.10398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
43 Shimada S, Tajiri K, Baba H, Minemura M, Tsuneyama K, Nakano M, Sugiyama T. Peritumoral Hyperplasia in Hepatic Sclerosed Hemangioma. ACG Case Rep J 2017;4:e61. [PMID: 28462238 DOI: 10.14309/crj.2017.61] [Reference Citation Analysis]
44 Naka S, Wato K, Hatakeyama R, Okawa R, Nomura R, Nakano K. Longitudinal comparison of Streptococcus mutans-induced aggravation of non-alcoholic steatohepatitis in mice. J Oral Microbiol 2018;10:1428005. [PMID: 29503703 DOI: 10.1080/20002297.2018.1428005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:179-87. [PMID: 30791782 DOI: 10.1080/17474124.2019.1549989] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
46 Kumar R, Goh BG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin Mol Hepatol 2020;26:196-208. [PMID: 31914720 DOI: 10.3350/cmh.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
47 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
48 Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
49 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
50 Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
51 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
52 Flores YN, Zhang ZF, Bastani R, Leng M, Crespi CM, Ramírez-Palacios P, Stevens H, Salmerón J. Risk factors for liver disease among adults of Mexican descent in the United States and Mexico. World J Gastroenterol 2018; 24(37): 4281-4290 [PMID: 30310261 DOI: 10.3748/wjg.v24.i37.4281] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
53 Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, Rodriguez-Agudo R, Bizkarguenaga M, Zubiete-Franco I, Gutiérrez-de Juan V, Cabrera D, Alonso C, Iruzubieta P, Romero-Gomez M, van Liempd S, Castro A, Nogueiras R, Varela-Rey M, Falcón-Pérez JM, Villa E, Crespo J, Lu SC, Mato JM, Aspichueta P, Delgado TC, Martínez-Chantar ML. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. Cell Metab 2020;31:605-622.e10. [PMID: 32084378 DOI: 10.1016/j.cmet.2020.01.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
54 Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110-117. [PMID: 23978719 DOI: 10.1016/j.jhep.2013.08.011] [Cited by in Crossref: 293] [Cited by in F6Publishing: 269] [Article Influence: 36.6] [Reference Citation Analysis]
55 Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014;18:157-163. [PMID: 24274871 DOI: 10.1016/j.cld.2013.09.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
56 Thoolen B, Ten Kate FJ, van Diest PJ, Malarkey DE, Elmore SA, Maronpot RR. Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol 2012;25:189-99. [PMID: 22988337 DOI: 10.1293/tox.25.189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
57 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Wongtrakul W, Niltwat S, Charatcharoenwitthaya P. The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:744713. [PMID: 34513896 DOI: 10.3389/fmed.2021.744713] [Reference Citation Analysis]
59 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
60 Ji G, Zhao X, Leng L, Liu P, Jiang Z. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011;10:23. [PMID: 21269482 DOI: 10.1186/1476-511X-10-23] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
61 Asfari MM, Talal Sarmini M, Alomari M, Lopez R, Dasarathy S, McCullough AJ. The association of nonalcoholic steatohepatitis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2020;32:1566-70. [PMID: 32073443 DOI: 10.1097/MEG.0000000000001681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Thomas R, Thomas RS, Auerbach SS, Portier CJ. Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species. PLoS One 2013;8:e63308. [PMID: 23737943 DOI: 10.1371/journal.pone.0063308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
63 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
64 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
65 Thomas SM, Moke D, Lopez R, Hanna R, Kabbany MN, Alkhouri N. Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study. J Adolesc Young Adult Oncol 2017;6:286-93. [PMID: 27996360 DOI: 10.1089/jayao.2016.0048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359-1368. [PMID: 25873639 DOI: 10.1136/gutjnl-2015-309265] [Cited by in Crossref: 217] [Cited by in F6Publishing: 189] [Article Influence: 36.2] [Reference Citation Analysis]
67 Kwon I, Jun DW, Moon JH. Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:308-14. [PMID: 30400736 DOI: 10.5009/gnl18175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
68 Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:3083. [PMID: 24419221 DOI: 10.1038/ncomms4083] [Cited by in Crossref: 304] [Cited by in F6Publishing: 263] [Article Influence: 50.7] [Reference Citation Analysis]
69 Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017;23:1015-1022. [PMID: 28340509 DOI: 10.1002/lt.24764] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
70 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 47.0] [Reference Citation Analysis]
71 Okuda K, Umemura A, Umemura S, Kataoka S, Taketani H, Seko Y, Nishikawa T, Yamaguchi K, Moriguchi M, Kanbara Y, Arbiser JL, Shima T, Okanoue T, Karin M, Itoh Y. Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis. Cancers (Basel) 2021;13:1515. [PMID: 33806040 DOI: 10.3390/cancers13071515] [Reference Citation Analysis]
72 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
73 Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet 2018;43:91-101. [PMID: 28702877 DOI: 10.1007/s13318-017-0429-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
74 Huang KT, Chen KD, Hsu LW, Kung CP, Li SR, Chen CC, Chiu KW, Goto S, Chen CL. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. Nutrients 2020;12:E270. [PMID: 31968655 DOI: 10.3390/nu12010270] [Reference Citation Analysis]
75 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
76 Zelber-Sagi S. Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. Semin Liver Dis 2021;41:248-62. [PMID: 34139786 DOI: 10.1055/s-0041-1729971] [Reference Citation Analysis]
77 Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115-125. [PMID: 27508181 DOI: 10.2147/jhc.s44381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 6.9] [Reference Citation Analysis]
78 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013.34] [Cited by in Crossref: 278] [Cited by in F6Publishing: 267] [Article Influence: 34.8] [Reference Citation Analysis]
79 Reeves HL, Zaki MYW, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci 2016;61:1234-45. [DOI: 10.1007/s10620-016-4085-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
80 Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149:1471-1482.e5; quiz e17-8. [PMID: 26255044 DOI: 10.1053/j.gastro.2015.07.056] [Cited by in Crossref: 239] [Cited by in F6Publishing: 229] [Article Influence: 39.8] [Reference Citation Analysis]
81 Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1. [PMID: 25148760 DOI: 10.1016/j.cgh.2014.08.013] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 20.4] [Reference Citation Analysis]
82 López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, Chávez-tapia NC, Arrese M, Uribe M, Méndez-sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13:166-78. [DOI: 10.1016/s1665-2681(19)30879-8] [Cited by in Crossref: 82] [Article Influence: 11.7] [Reference Citation Analysis]
83 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
84 Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, Osna NA, Kharbanda KK, Seth D, Bautista A. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97:492-510. [PMID: 25217800 DOI: 10.1016/j.yexmp.2014.09.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
85 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690. [PMID: 24042449 DOI: 10.1038/nrgastro.2013.171] [Cited by in Crossref: 926] [Cited by in F6Publishing: 894] [Article Influence: 115.8] [Reference Citation Analysis]
86 Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA. Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med 2016;32:110-5. [PMID: 27413728 DOI: 10.1159/000445407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
87 Dembek A, Laggai S, Kessler SM, Czepukojc B, Simon Y, Kiemer AK, Hoppstädter J. Hepatic interleukin-6 production is maintained during endotoxin tolerance and facilitates lipid accumulation. Immunobiology 2017;222:786-96. [DOI: 10.1016/j.imbio.2017.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
88 Liu P, Xu Y, Tang Y, Du M, Yu X, Sun J, Xiao L, He M, Wei S, Yuan J, Wang Y, Liang Y, Wu T, Miao X, Yao P. Independent and joint effects of moderate alcohol consumption and smoking on the risks of non-alcoholic fatty liver disease in elderly Chinese men. PLoS One 2017;12:e0181497. [PMID: 28727853 DOI: 10.1371/journal.pone.0181497] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
89 Corey KE, Kaplan LM. Obesity and Liver Disease. Clinics in Liver Disease 2014;18:1-18. [DOI: 10.1016/j.cld.2013.09.019] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
90 Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00505-X. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
91 Núñez-Torres R, Macías J, Rivero-Juarez A, Neukam K, Merino D, Téllez F, Merchante N, Gómez-Mateos J, Rivero A, Pineda JA, Real LM; Group for the Study of Viral Hepatitis (HEPAVIR) of The Andalusian Society of Infectious Diseases (SAEI). Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. HIV Med 2017;18:546-54. [PMID: 28116842 DOI: 10.1111/hiv.12489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int. 2014;2014:106247. [PMID: 24738043 DOI: 10.1155/2014/106247] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
93 Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J Hepatol 2015; 7(3): 593-599 [PMID: 25848483 DOI: 10.4254/wjh.v7.i3.593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
94 Luo T, Chen J, Liu JJ, Li H, You XM, Wang HL, Zhu SL, Li LQ. Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis. Onco Targets Ther 2016;9:4483-9. [PMID: 27499641 DOI: 10.2147/OTT.S108754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7(11): 1521-1529 [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
96 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
97 Kim JM, Cho BI, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK. Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma. Am J Surg. 2015;209:391-397. [PMID: 25682096 DOI: 10.1016/j.amjsurg.2013.06.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
98 Shimada T, Maruyama H, Kondo T, Sekimoto T, Takahashi M, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Chiba T, Kanai F, Okabe S, Yoshikawa M, Yokosuka O. Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan. Hepatol Int 2013;7:1030-9. [DOI: 10.1007/s12072-013-9470-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
99 Wu W, Chen J, Ye W, Li X, Zhang J. Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study. Breast Cancer Res Treat 2017;166:289-97. [PMID: 28741275 DOI: 10.1007/s10549-017-4411-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
100 Guo XY, Sun F, Chen JN, Wang YQ, Pan Q, Fan JG. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World J Gastroenterol 2018; 24(3): 323-337 [PMID: 29391755 DOI: 10.3748/wjg.v24.i3.323] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
101 Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 2017;65:2100-9. [DOI: 10.1002/hep.29068] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
102 Lee CW, Tsai HI, Lee WC, Huang SW, Lin CY, Hsieh YC, Kuo T, Chen CW, Yu MC. Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal? J Clin Med 2019;8:E1736. [PMID: 31635078 DOI: 10.3390/jcm8101736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
103 Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL, de Lédinghen V. Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology 2012;107:1862-71. [DOI: 10.1038/ajg.2012.331] [Cited by in Crossref: 231] [Cited by in F6Publishing: 205] [Article Influence: 25.7] [Reference Citation Analysis]
104 Wang H, Chen YE, Eitzman DT. Imaging body fat: techniques and cardiometabolic implications. Arterioscler Thromb Vasc Biol 2014;34:2217-23. [PMID: 25147343 DOI: 10.1161/ATVBAHA.114.303036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
105 Chung SI, Moon H, Kim DY, Cho KJ, Ju HL, Kim DY, Ahn SH, Han KH, Ro SW. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterol 2016;16:13. [PMID: 26821924 DOI: 10.1186/s12876-016-0423-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
106 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
107 Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci. 2014;105:1254-1260. [PMID: 25117675 DOI: 10.1111/cas.12498] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
108 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
109 Vanni E, Bugianesi E. Obesity and Liver Cancer. Clinics in Liver Disease 2014;18:191-203. [DOI: 10.1016/j.cld.2013.09.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
110 Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, Vaidya D. Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol. 2015;13:1686-1693.e2. [PMID: 25592661 DOI: 10.1016/j.cgh.2014.12.033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
111 Kessler SM, Simon Y, Gemperlein K, Gianmoena K, Cadenas C, Zimmer V, Pokorny J, Barghash A, Helms V, van Rooijen N. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma. Int J Mol Sci. 2014;15:5762-5773. [PMID: 24714086 DOI: 10.3390/ijms15045762] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
112 Liu L, He C, Liu H, Wang G, Lv Z, Ni Y, Mou L, Zhan Y, Liu J. Transcriptomic profiling of long non-coding RNAs in non-virus associated hepatocellular carcinoma. Cell Biochem Biophys 2020;78:465-74. [PMID: 32405957 DOI: 10.1007/s12013-020-00915-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Nguyen PT, Kanno K, Pham QT, Kikuchi Y, Kakimoto M, Kobayashi T, Otani Y, Kishikawa N, Miyauchi M, Arihiro K, Ito M, Tazuma S. Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:3255-68. [PMID: 32870388 DOI: 10.1007/s00432-020-03374-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
114 Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, Re VL 3rd, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med 2020;35:2025-34. [PMID: 32342483 DOI: 10.1007/s11606-020-05782-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223-231. [PMID: 21476917 DOI: 10.1586/egh.11.8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
116 Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2019;25:80-9. [PMID: 30190369 DOI: 10.1158/1078-0432.CCR-18-0847] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
117 Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26 Suppl 1:153-162. [PMID: 21199527 DOI: 10.1111/j.1440-1746.2010.06547.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 7.5] [Reference Citation Analysis]
118 Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177:333-342. [PMID: 23355498 DOI: 10.1093/aje/kws252] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 13.3] [Reference Citation Analysis]
119 Seitz HK. The role of cytochrome P4502E1 in the pathogenesis of alcoholic liver disease and carcinogenesis. Chem Biol Interact 2020;316:108918. [PMID: 31836462 DOI: 10.1016/j.cbi.2019.108918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
120 Kinoshita A, Onoda H, Ueda K, Imai N, Iwaku A, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Clinical characteristics and survival outcomes of super-elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatol Res 2016;46:E5-E14. [PMID: 25753133 DOI: 10.1111/hepr.12514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Lefkowitch JH. Advances in hepatobiliary pathology: update for 2010. Clin Liver Dis 2010;14:747-62. [PMID: 21055694 DOI: 10.1016/j.cld.2010.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Hwang JA, Min JH, Kang TW, Jeong WK, Kim YK, Ko SE, Choi SY. Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. Eur Radiol 2021. [PMID: 33856517 DOI: 10.1007/s00330-021-07897-8] [Reference Citation Analysis]
123 Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Ohkawara Y, Yamaguchi K, Minami M, Okanoue T. Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18(16): 1926-1932 [PMID: 22563173 DOI: 10.3748/wjg.v18.i16.1926] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
124 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Chiappini F, Desterke C, Bertrand-Michel J, Guettier C, Le Naour F. Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Sci Rep 2016;6:31587. [PMID: 27510159 DOI: 10.1038/srep31587] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
126 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
127 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
128 Lee S, Kim S, Hwang S, Cherrington NJ, Ryu DY. Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease. Oncotarget 2017;8:63370-81. [PMID: 28968997 DOI: 10.18632/oncotarget.18812] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
129 Yu DC, Liu J, Chen J, Shao JJ, Shen X, Xia HG, Li CJ, Xue B, Ding YT. GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer 2014;14:248. [PMID: 24716791 DOI: 10.1186/1471-2407-14-248] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
130 Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol. 2013;28 Suppl 4:88-92. [PMID: 24251711 DOI: 10.1111/jgh.12239] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
131 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 30.2] [Reference Citation Analysis]
132 Selvakumar PKC, Kabbany MN, Nobili V, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children. Pediatric Clinics of North America 2017;64:659-75. [DOI: 10.1016/j.pcl.2017.01.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
133 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
134 Kumar R. Hard clinical outcomes in patients with NAFLD. Hepatol Int 2013;7 Suppl 2:790-9. [PMID: 26202293 DOI: 10.1007/s12072-013-9455-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
135 Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7392-7402 [PMID: 24966609 DOI: 10.3748/wjg.v20.i23.7392] [Cited by in CrossRef: 206] [Cited by in F6Publishing: 186] [Article Influence: 29.4] [Reference Citation Analysis]
136 Tian YE, Xie XU, Lin Y, Tan G, Zhong WU. Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives. Oncol Lett 2015;9:1983-8. [PMID: 26136999 DOI: 10.3892/ol.2015.3025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
137 Hoki T, Katsuta E, Yan L, Takabe K, Ito F. Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma. J Surg Res 2019;234:343-52. [PMID: 30527495 DOI: 10.1016/j.jss.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
138 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 165.3] [Reference Citation Analysis]
139 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
140 Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37:936-949. [PMID: 28371239 DOI: 10.1111/liv.13435] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 27.3] [Reference Citation Analysis]
141 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Yamada S, Kimura M, Saito Y, Saito H. Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. J Clin Biochem Nutr 2018;63:123-8. [PMID: 30279623 DOI: 10.3164/jcbn.17-125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Sicklick JK. Correcting the misnomers of epithelial–mesenchymal relations. Journal of Surgical Research 2013;182:36-9. [DOI: 10.1016/j.jss.2012.02.063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
144 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1057] [Article Influence: 563.0] [Reference Citation Analysis]
145 Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer 2016;5:21-36. [PMID: 26989657 DOI: 10.1159/000367756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
146 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
147 Lin LJ, Lin Y, Jin Y, Zheng CQ. Investigation of key microRNAs associated with hepatocellular carcinoma using small RNA-seq data. Mol Biol Rep 2014;41:4341-9. [PMID: 24623406 DOI: 10.1007/s11033-014-3305-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
148 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
149 Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014;14:121-131. [PMID: 23292294 DOI: 10.1007/s10238-012-0227-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
150 Papadatos D, Fowler KJ, Kielar AZ, Cui J, Sirlin CB. Cirrhosis and LI-RADS. Abdom Radiol (NY) 2018;43:26-40. [PMID: 29218367 DOI: 10.1007/s00261-017-1425-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
151 Mair RD, Valenzuela A, Ha NB, Ayoub WS, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012;10:1412-7. [PMID: 22902757 DOI: 10.1016/j.cgh.2012.08.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
152 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
153 Kroh A, Walter J, Schüler H, Nolting J, Eickhoff R, Heise D, Neumann UP, Cramer T, Ulmer TF, Fragoulis A. A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. Int J Mol Sci 2019;20:E5658. [PMID: 31726709 DOI: 10.3390/ijms20225658] [Reference Citation Analysis]
154 Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol 2016;51:586-96. [PMID: 26456168 DOI: 10.1007/s00535-015-1129-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
155 Eguchi A, Feldstein AE. Adipocyte cell death, fatty liver disease and associated metabolic disorders. Dig Dis 2014;32:579-85. [PMID: 25034291 DOI: 10.1159/000360509] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
156 Goossens N, Hoshida Y. Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology 2016;150:1710-7. [PMID: 26784140 DOI: 10.1053/j.gastro.2016.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
157 Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2:43-51. [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
158 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int 2016;36:1688-95. [PMID: 27064133 DOI: 10.1111/liv.13144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
160 Hosseini N, Shor J, Szabo G. Alcoholic Hepatitis: A Review. Alcohol Alcohol 2019;54:408-16. [PMID: 31219169 DOI: 10.1093/alcalc/agz036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
161 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 156] [Article Influence: 82.5] [Reference Citation Analysis]
162 Holterman AL, Holterman M, Browne A, Henriques S, Guzman G, Fantuzzi G. Patterns of surgical weight loss and resolution of metabolic abnormalities in superobese bariatric adolescents. Journal of Pediatric Surgery 2012;47:1633-9. [DOI: 10.1016/j.jpedsurg.2012.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
163 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
164 Takamoto T, Makuuchi M. Precision surgery for primary liver cancer. Cancer Biol Med 2019;16:475-85. [PMID: 31565478 DOI: 10.20892/j.issn.2095-3941.2019.0194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res. 2013;37 Suppl 1:E247-E252. [PMID: 23320802 DOI: 10.1111/j.1530-0277.2012.01900.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
166 Chiang C, Huang H, Huang T, Shih Y, Hsieh T, Lin H. Nonalcoholic Fatty Liver Disease Associated With Bladder Cancer. The American Journal of the Medical Sciences 2020;360:161-5. [DOI: 10.1016/j.amjms.2020.04.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
167 Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(18): 2155-2161 [PMID: 26328027 DOI: 10.4254/wjh.v7.i18.2155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
168 Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-318. [PMID: 23458891 DOI: 10.1038/nrgastro.2013. 34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:107-20. [DOI: 10.1002/hep.30036] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 51.7] [Reference Citation Analysis]
170 Tan EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. J Gastroenterol Hepatol 2021;36:751-7. [PMID: 32583444 DOI: 10.1111/jgh.15160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Kai T, Yamazaki T, Arai S, Miyazaki T. Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc. PLoS One 2014;9:e97037. [PMID: 24804991 DOI: 10.1371/journal.pone.0097037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
172 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:1617-24. [PMID: 24464211 DOI: 10.1007/s10620-014-3031-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
174 Ding Y, Sun X, Chen Y, Deng Y, Qian K. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Eur J Pharmacol 2015;761:405-12. [PMID: 25967348 DOI: 10.1016/j.ejphar.2015.05.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
175 Wong CR, Nguyen MH, Lim JK. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(37): 8294-8303 [PMID: 27729736 DOI: 10.3748/wjg.v22.i37.8294] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
176 Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J 2016;40:1-11. [PMID: 26912150 DOI: 10.4093/dmj.2016.40.1.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
177 Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, Schwimmer JB. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384-391. [PMID: 22521357 DOI: 10.1016/j.jhep.2012.03.024] [Cited by in Crossref: 146] [Cited by in F6Publishing: 134] [Article Influence: 16.2] [Reference Citation Analysis]
178 Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. OMICS 2019;23:181-9. [PMID: 30932742 DOI: 10.1089/omi.2019.0035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
179 Wang C, Tseng T, Kao J. Hepatitis B virus infection and metabolic syndrome: Fact or fiction?: Hepatitis B virus and metabolic syndrome. J Gastroenterol Hepatol 2015;30:14-20. [DOI: 10.1111/jgh.12700] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
180 Ye Y, Xu Y, Lai Y, He W, Li Y, Wang R, Luo X, Chen R, Chen T. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem. 2018;119:2951-2963. [PMID: 29131381 DOI: 10.1002/jcb.26509] [Cited by in Crossref: 62] [Cited by in F6Publishing: 76] [Article Influence: 15.5] [Reference Citation Analysis]
181 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
182 Smith RJ. Nutrition and metabolism in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013;2:89-96. [PMID: 24570922 DOI: 10.3978/j.issn.2304-3881.2012.11.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
183 Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010;4:623-635. [PMID: 20932147 DOI: 10.1586/egh.10.56] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
184 Byun J, Lee SS, Sung YS, Shin Y, Yun J, Kim HS, Yu ES, Lee SG, Lee MG. CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard. Eur Radiol 2019;29:4427-35. [PMID: 30569183 DOI: 10.1007/s00330-018-5905-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
185 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
186 Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71:907-916. [PMID: 31309602 DOI: 10.1002/hep.30858] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
187 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.6] [Reference Citation Analysis]
188 Park JG, Kim G, Jang SY, Lee YR, Lee E, Lee HW, Han MH, Chun JM, Han YS, Yoon JS, Kang MK, Kweon YO, Tak WY, Park SY, Hur K. Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis. Life (Basel) 2020;10:E230. [PMID: 33022942 DOI: 10.3390/life10100230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 2011;3:1167-84. [PMID: 21995570 DOI: 10.2217/imt.11.117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
190 Güthle M, Dollinger MM. [Epidemiology and risk factors of hepatocellular carcinoma]. Radiologe 2014;54:654-9. [PMID: 24973122 DOI: 10.1007/s00117-014-2650-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
191 Fung J, Lee C, Chan M, Seto W, Lai C, Yuen M; the Hong Kong Liver Health Census Study Group. High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census. Liver Int 2015;35:542-9. [DOI: 10.1111/liv.12619] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
192 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
193 Hyun J, Wang S, Kim J, Rao KM, Park SY, Chung I, Ha CS, Kim SW, Yun YH, Jung Y. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun 2016;7:10993. [PMID: 27001906 DOI: 10.1038/ncomms10993] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 24.0] [Reference Citation Analysis]
194 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 9.4] [Reference Citation Analysis]
195 Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, Hamdorf J, Adams LA. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol 2018;113:1484-93. [PMID: 29899440 DOI: 10.1038/s41395-018-0133-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
196 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 61.0] [Reference Citation Analysis]
197 Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim 2019;68:147-58. [PMID: 30487357 DOI: 10.1538/expanim.18-0108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
198 Cimini FA, Barchetta I, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertoccini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes Metab Res Rev 2021;37:e3358. [PMID: 32469428 DOI: 10.1002/dmrr.3358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
199 Flores YN, Velázquez-Cruz R, Ramírez P, Bañuelos M, Zhang ZF, Yee HF Jr, Chang SC, Canizales-Quinteros S, Quiterio M, Cabrera-Alvarez G, Patiño N, Salmerón J. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults. Mol Biol Rep 2016;43:1359-69. [PMID: 27752939 DOI: 10.1007/s11033-016-4058-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
200 Vilar-gomez E, Calzadilla-bertot L, Wai-sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-fabian L, Alvarez-quiñones Sanz M, Conde-martin AF, De Boer B, Mcleod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-gomez M. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 2018;155:443-457.e17. [DOI: 10.1053/j.gastro.2018.04.034] [Cited by in Crossref: 235] [Cited by in F6Publishing: 231] [Article Influence: 78.3] [Reference Citation Analysis]
201 Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536-542. [PMID: 23623998 DOI: 10.1016/j.jhep.2013.04.013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 155] [Article Influence: 19.3] [Reference Citation Analysis]
202 Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015;49:1405-1418. [PMID: 26223319 DOI: 10.3109/10715762.2015.1078461] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 24.2] [Reference Citation Analysis]
203 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
204 Hoki T, Miyanishi K, Tanaka S, Takada K, Kawano Y, Sakurada A, Sato M, Kubo T, Sato T, Sato Y, Takimoto R, Kobune M, Kato J. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis: HEPATOLOGY, Vol. XX, No. X, 2015. Hepatology 2015;62:751-61. [DOI: 10.1002/hep.27774] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
205 Su C, Chau G, Hung H, Yeh Y, Lei H, Hsia C, Lai C, Lin H, Wu J. Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Ann Surg Oncol 2015;22:2253-61. [DOI: 10.1245/s10434-014-4221-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
206 Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int 2017;37:80-9. [PMID: 27264722 DOI: 10.1111/liv.13183] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
207 Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer Lett 2014;345:230-4. [PMID: 23941829 DOI: 10.1016/j.canlet.2013.07.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
208 Canbay A, Sowa JP, Syn WK, Treckmann J. NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? Visc Med. 2016;32:234-238. [PMID: 27722159 DOI: 10.1159/000446379] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
209 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
210 Chan AWH, Wong GLH, Chan H, Tong JHM, Yu Y, Choi PCL, Chan HLY, To K, Wong VWS. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B: Steatosis and cancer in hepatitis B. Journal of Gastroenterology and Hepatology 2017;32:667-76. [DOI: 10.1111/jgh.13536] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 19.8] [Reference Citation Analysis]
211 Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014;27:420-32. [PMID: 24051694 DOI: 10.1038/modpathol.2013.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
212 Wang G, Zhu S, Li X. Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors. Oncol Lett 2019;17:1184-8. [PMID: 30655882 DOI: 10.3892/ol.2018.9690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
213 VanWagner LB, Terry JG, Chow LS, Alman AC, Kang H, Ingram KH, Shay C, Lewis CE, Bryan RN, Launer LJ, Jeffrey Carr J. Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: The CARDIA study. Obesity (Silver Spring). 2017;25:642-651. [PMID: 28169509 DOI: 10.1002/oby.21767] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
214 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
215 Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-30. [PMID: 22349170 DOI: 10.1038/nrgastro.2012.14] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
216 Draijer LG, Haggenburg S, Benninga MA, Chegary M, Koot BGP. Survey on screening for paediatric non-alcoholic fatty liver disease in clinical practice in Dutch hospitals. Acta Paediatr 2020;109:2388-93. [PMID: 32271954 DOI: 10.1111/apa.15294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology. 2012;56:2221-2230. [PMID: 22767263 DOI: 10.1002/hep.25935] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
218 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188-2195. [PMID: 24375711 DOI: 10.1002/hep.26986] [Cited by in Crossref: 437] [Cited by in F6Publishing: 394] [Article Influence: 62.4] [Reference Citation Analysis]
219 Tarapure S, Tubaki BR, Khot S. Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) - A single arm clinical trial. J Ayurveda Integr Med 2021;12:136-42. [PMID: 33579578 DOI: 10.1016/j.jaim.2020.12.015] [Reference Citation Analysis]
220 Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577-1586. [PMID: 27543837 DOI: 10.1002/hep.28785] [Cited by in Crossref: 459] [Cited by in F6Publishing: 451] [Article Influence: 91.8] [Reference Citation Analysis]
221 Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14:124-31.e1. [PMID: 26196445 DOI: 10.1016/j.cgh.2015.07.019] [Cited by in Crossref: 260] [Cited by in F6Publishing: 246] [Article Influence: 43.3] [Reference Citation Analysis]
222 Lee CW, Chan KM, Tsai HI, Hsieh YC, Lin CY, Kuo YC, Hsu HY, Yu MC. Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified? Aging (Albany NY) 2019;11:1537-50. [PMID: 30867335 DOI: 10.18632/aging.101854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
223 Ozawa T, Maehara N, Kai T, Arai S, Miyazaki T. Dietary fructose-induced hepatocellular carcinoma development manifested in mice lacking apoptosis inhibitor of macrophage (AIM). Genes Cells 2016;21:1320-32. [PMID: 27813205 DOI: 10.1111/gtc.12446] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
224 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 66] [Article Influence: 11.7] [Reference Citation Analysis]
225 Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int 2015;35:1862-71. [PMID: 25524812 DOI: 10.1111/liv.12764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
226 Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, Yamada S, Niizeki T, Torimura T, Sata M. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One. 2011;6:e26840. [PMID: 22110596 DOI: 10.1371/journal.pone.0026840] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
227 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 49.0] [Reference Citation Analysis]
228 Linhart K, Bartsch H, Seitz HK. The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol. 2014;3:56-62. [PMID: 25462066 DOI: 10.1016/j.redo-x.2014.08.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1374] [Article Influence: 295.6] [Reference Citation Analysis]
230 Berkan-Kawińska A, Piekarska A. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin 2020;36:235-43. [PMID: 31631714 DOI: 10.1080/03007995.2019.1683817] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
231 Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int 2013;7 Suppl 2:823-32. [PMID: 26202297 DOI: 10.1007/s12072-013-9453-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
232 Kim JW, Lee YS, Park YS, Kim BH, Lee SY, Yeon JE, Lee CH. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. Sci Rep 2020;10:2671. [PMID: 32060386 DOI: 10.1038/s41598-020-59601-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
233 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Fleet SE, Lefkowitch JH, Lavine JE. Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2017;46:217-31. [DOI: 10.1016/j.gtc.2017.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
235 Miñambres I, Rubio MA, de Hollanda A, Breton I, Vilarrasa N, Pellitero S, Bueno M, Lecube A, Marcuello C, Goday A, Ballesteros MD, Soriano G, Caixàs A. Outcomes of Bariatric Surgery in Patients with Cirrhosis. OBES SURG 2019;29:585-92. [DOI: 10.1007/s11695-018-3562-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
236 Desterke C, Chiappini F. Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. Int J Mol Sci 2019;20:E5594. [PMID: 31717414 DOI: 10.3390/ijms20225594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
237 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2:633-6. [PMID: 25054002 DOI: 10.3892/br.2014.309] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
239 Beilfuss A, Sowa J, Sydor S, Beste M, Bechmann LP, Schlattjan M, Syn W, Wedemeyer I, Mathé Z, Jochum C, Gerken G, Gieseler RK, Canbay A. Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 2015;64:791-9. [DOI: 10.1136/gutjnl-2014-307024] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 11.1] [Reference Citation Analysis]
240 Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
241 Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol 2021;27:110-24. [PMID: 33317254 DOI: 10.3350/cmh.2020.0125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-433; quiz e50. [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023] [Cited by in Crossref: 258] [Cited by in F6Publishing: 239] [Article Influence: 25.8] [Reference Citation Analysis]
243 Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol 2013;48:515-25. [PMID: 22911170 DOI: 10.1007/s00535-012-0653-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
244 Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Kaneko S. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0191026. [PMID: 29342182 DOI: 10.1371/journal.pone.0191026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
245 Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hübscher SG. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550-1561. [PMID: 24650559 DOI: 10.1016/j.ajpath.2014.01.034] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
246 Emma MR, Giannitrapani L, Cabibi D, Porcasi R, Pantuso G, Augello G, Giglio RV, Re NL, Capitano AR, Montalto G, Soresi M, Cervello M. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158792. [PMID: 32777481 DOI: 10.1016/j.bbalip.2020.158792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
247 Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014;31:971. [PMID: 24798875 DOI: 10.1007/s12032-014-0971-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
248 Ivanics T, Abreu P, De Martin E, Sapisochin G. Changing Trends in Liver Transplantation: Challenges and Solutions. Transplantation 2021;105:743-56. [PMID: 32910093 DOI: 10.1097/TP.0000000000003454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
249 Cotter TG, Charlton M. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl 2019;26:141-59. [DOI: 10.1002/lt.25657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
250 Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Navas Jimenez C, Sakka M, Bouam S, Retbi A, Krasteva D, Meritet JF, Schwarzinger M, Thabut D, Rufat P, Bonnefont-Rousselot D, Sogni P, Pol S, Tsochatzis E; Demosthenes research group. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol 2021:S0168-8278(21)02092-4. [PMID: 34606913 DOI: 10.1016/j.jhep.2021.09.030] [Reference Citation Analysis]
251 Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, Boekschoten MV, Müller M, Streetz KL, Trautwein C. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol 2014;61:883-90. [PMID: 24845607 DOI: 10.1016/j.jhep.2014.05.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
252 Schnabl B, Farshchi-heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling CA, Vera DR. Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. Nuclear Medicine and Biology 2016;43:179-87. [DOI: 10.1016/j.nucmedbio.2015.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
253 Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009: Hepatology, Vol. XX, No. X, 2015 Younossi et al. Hepatology 2015;62:1723-30. [DOI: 10.1002/hep.28123] [Cited by in Crossref: 371] [Cited by in F6Publishing: 339] [Article Influence: 61.8] [Reference Citation Analysis]
254 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
255 Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
256 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
257 Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 2014;63:530-2. [DOI: 10.1136/gutjnl-2013-305718] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
258 Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014;25:473-86. [PMID: 24802098 DOI: 10.1007/s00335-014-9521-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
259 Sundelin EIO, Gormsen LC, Heebøll S, Vendelbo MH, Jakobsen S, Munk OL, Feddersen S, Brøsen K, Hamilton-Dutoit SJ, Pedersen SB, Grønbaek H, Jessen N. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. Br J Clin Pharmacol 2019;85:1761-70. [PMID: 30973968 DOI: 10.1111/bcp.13962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
260 Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40. [DOI: 10.1093/carcin/bgx007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 47] [Article Influence: 26.0] [Reference Citation Analysis]
261 Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS One 2017;12:e0186715. [PMID: 29077714 DOI: 10.1371/journal.pone.0186715] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
262 Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med 2021;10:7308-19. [PMID: 34535983 DOI: 10.1002/cam4.4256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Laish I, Mannasse-Green B, Hadary R, Konikoff FM, Amiel A, Kitay-Cohen Y. Aneuploidy and asynchronous replication in non-alcholic fatty liver disease and cryptogenic cirrhosis. Gene 2016;593:162-6. [PMID: 27520584 DOI: 10.1016/j.gene.2016.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
264 Barr DC, Hussain HK. Magnetic Resonance Imaging in Cirrhosis: What’s New? Topics in Magnetic Resonance Imaging 2014;23:129-49. [DOI: 10.1097/rmr.0000000000000017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
265 Lee C, Kim J, Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells 2019;8:E1259. [PMID: 31619023 DOI: 10.3390/cells8101259] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
266 Diwan TS, Lee TC, Nagai S, Benedetti E, Posselt A, Bumgardner G, Noria S, Whitson BA, Ratner L, Mason D, Friedman J, Woodside KJ, Heimbach J. Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic.Am J Transplant. 2020;20:2143-2155. [PMID: 31965711 DOI: 10.1111/ajt.15784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
267 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
268 Han Y, Shi JP, Ma AL, Xu Y, Ding XD, Fan JG. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig 2014;34:1-7. [PMID: 24081374 DOI: 10.1007/s40261-013-0136-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
269 Ip BC, Wang XD. Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients. 2014;6:124-162. [PMID: 24379011 DOI: 10.3390/nu6010124] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
270 Barr DC, Hussain HK. MR Imaging in Cirrhosis and Hepatocellular Carcinoma. Magnetic Resonance Imaging Clinics of North America 2014;22:315-35. [DOI: 10.1016/j.mric.2014.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
271 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:837-61. [DOI: 10.1016/j.cgh.2017.08.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
272 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
273 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01153-8. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Reference Citation Analysis]
274 Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, Hur C. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Netw Open 2019;2:e190047. [PMID: 30794300 DOI: 10.1001/jamanetworkopen.2019.0047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
275 Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15:273-281.e1. [PMID: 27521507 DOI: 10.1016/j.cgh.2016.07.033] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
276 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 2017; 23(8): 1458-1468 [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
277 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21. [PMID: 31475372 DOI: 10.1111/apt.15464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
278 Lee JI, Yu JH, Anh SG, Lee HW, Jeong J, Lee KS. Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. Oncologist 2019;24:e653-61. [PMID: 30679317 DOI: 10.1634/theoncologist.2018-0370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
279 Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218-225. [PMID: 30643981 DOI: 10.1007/s00535-018-01542-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
280 Fukuzawa K, Hayashi T, Takahashi J, Yoshihara C, Tano M, Kotoku J, Saitoh S. Evaluation of six-point modified dixon and magnetic resonance spectroscopy for fat quantification: a fat–water–iron phantom study. Radiol Phys Technol 2017;10:349-58. [DOI: 10.1007/s12194-017-0410-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
281 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 63.7] [Reference Citation Analysis]
282 Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013;8:e62885. [PMID: 23638162 DOI: 10.1371/journal.pone.0062885] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 20.8] [Reference Citation Analysis]
283 Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res 2021;51:1013-25. [PMID: 34533266 DOI: 10.1111/hepr.13688] [Reference Citation Analysis]
284 Shimada S, Kamiyama T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy. World J Surg Oncol 2020;18:122. [PMID: 32522259 DOI: 10.1186/s12957-020-01899-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
285 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-665. [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183] [Cited by in Crossref: 559] [Cited by in F6Publishing: 528] [Article Influence: 69.9] [Reference Citation Analysis]
286 Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? Hepatology. 2017;65:2090-2099. [PMID: 28100008 DOI: 10.1002/hep.29055] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
287 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
288 Fernández-Tussy P, Fernández-Ramos D, Lopitz-Otsoa F, Simón J, Barbier-Torres L, Gomez-Santos B, Nuñez-Garcia M, Azkargorta M, Gutiérrez-de Juan V, Serrano-Macia M, Rodríguez-Agudo R, Iruzubieta P, Anguita J, Castro RE, Champagne D, Rincón M, Elortza F, Arslanow A, Krawczyk M, Lammert F, Kirchmeyer M, Behrmann I, Crespo J, Lu SC, Mato JM, Varela-Rey M, Aspichueta P, Delgado TC, Martínez-Chantar ML. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Mol Metab 2019;29:40-54. [PMID: 31668391 DOI: 10.1016/j.molmet.2019.08.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
289 Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Papadopoulou M, Pavlidis A, Kostaki S, Bozikas A, Savopoulos C, Hatzitolios AI. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol 2013; 5(11): 621-626 [PMID: 24303090 DOI: 10.4254/wjh.v5.i11.621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
290 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
291 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? Journal of Hepatology 2018;68:326-34. [DOI: 10.1016/j.jhep.2017.10.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 25.3] [Reference Citation Analysis]
292 Praktiknjo M, Djayadi N, Mohr R, Schierwagen R, Bischoff J, Dold L, Pohlmann A, Schwarze-Zander C, Wasmuth JC, Boesecke C, Rockstroh JK, Trebicka J. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int. 2019;39:1514-1520. [PMID: 30916873 DOI: 10.1111/liv.14107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
293 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
294 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-556. [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027] [Cited by in Crossref: 277] [Cited by in F6Publishing: 258] [Article Influence: 34.6] [Reference Citation Analysis]
295 De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:1872-1880. [PMID: 28527050 DOI: 10.1007/s10620-017-4615-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
296 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
297 Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5:270. [PMID: 28758096 DOI: 10.21037/atm.2017.04.41] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
298 Jin M, Niu X, Liu Y, Zhang D, Yuan D, Shen H. Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet. Open Med (Wars) 2020;15:689-96. [PMID: 33336025 DOI: 10.1515/med-2020-0212] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Linhart K, Bartsch H, Seitz HK. The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol 2014;3:56-62. [PMID: 25462066 DOI: 10.1016/j.redox.2014.08.009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 11.7] [Reference Citation Analysis]
300 Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23:48-62. [PMID: 26771116 DOI: 10.1016/j.cmet.2015.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 171] [Article Influence: 39.4] [Reference Citation Analysis]
301 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 290] [Article Influence: 50.3] [Reference Citation Analysis]
302 Ratziu V, Pienar L. Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? Hepatol Res 2011;41:687-95. [PMID: 21711428 DOI: 10.1111/j.1872-034X.2011.00825.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
303 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
304 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
305 Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210. [PMID: 25884354 DOI: 10.1186/s12885-015-1197-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
306 Besse-Patin A, Estall JL. An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. Int J Cell Biol 2014;2014:519153. [PMID: 24672550 DOI: 10.1155/2014/519153] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
307 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
308 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
309 Oliveira CP, Stefano JT, Carrilho FJ. Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surg Nutr 2017;6:350-2. [PMID: 29152487 DOI: 10.21037/hbsn.2017.06.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
310 Smereka P, Doshi AM, Lavelle LP, Shanbhogue K. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. AJR Am J Roentgenol 2020;215:382-9. [PMID: 32432909 DOI: 10.2214/AJR.19.22033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
311 Yoon CH, Jin YJ, Lee JW. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area. Eur J Gastroenterol Hepatol 2018;30:1090-6. [PMID: 29847489 DOI: 10.1097/MEG.0000000000001174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
312 Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol 2017; 9(7): 385-390 [PMID: 28321274 DOI: 10.4254/wjh.v9.i7.385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
313 Seitz HK, Mueller S, Hellerbrand C, Liangpunsakul S. Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD). Hepatobiliary Surg Nutr 2015;4:147-51. [PMID: 26151054 DOI: 10.3978/j.issn.2304-3881.2014.12.01] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
314 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013; 19(9): 1359-1371 [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
315 Holmer M, Melum E, Isoniemi H, Ericzon BG, Castedal M, Nordin A, Aagaard Schultz N, Rasmussen A, Line PD, Stål P, Bennet W, Hagström H. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int 2018;38:2082-90. [PMID: 29630771 DOI: 10.1111/liv.13751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
316 Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 2016;29:77-89. [PMID: 27429211 DOI: 10.1016/j.coph.2016.07.005] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 20.0] [Reference Citation Analysis]
317 Barat M, Nguyen TTL, Hollande C, Coty JB, Hoeffel C, Terris B, Dohan A, Mallet V, Pol S, Soyer P. LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? Eur J Radiol 2021;138:109651. [PMID: 33740627 DOI: 10.1016/j.ejrad.2021.109651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Nissar AU, Sharma L, Tasduq SA. Palmitic acid induced lipotoxicity is associated with altered lipid metabolism, enhanced CYP450 2E1 and intracellular calcium mediated ER stress in human hepatoma cells. Toxicol Res 2015;4:1344-58. [DOI: 10.1039/c5tx00101c] [Cited by in Crossref: 12] [Article Influence: 2.0] [Reference Citation Analysis]
319 Farrell G. Insulin Resistance, Obesity, and Liver Cancer. Clinical Gastroenterology and Hepatology 2014;12:117-9. [DOI: 10.1016/j.cgh.2013.07.040] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
320 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
321 Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, Takeshita Y, Shimakami T, Takatori H, Arai K, Kitamura K, Yamashita T, Yamashita T, Takamura M, Mizukoshi E, Takamura T, Honda M, Wada T, Kaneko S. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e26835. [PMID: 34397849 DOI: 10.1097/MD.0000000000026835] [Reference Citation Analysis]
322 Kinoshita A, Koike K, Nishino H. Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatr Gerontol Int 2017;17:189-201. [PMID: 26847184 DOI: 10.1111/ggi.12747] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
323 Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol 2017;23:290-301. [PMID: 28994271 DOI: 10.3350/cmh.2017.0042] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
324 Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol. 2012;47:718-728. [PMID: 22472070 DOI: 10.3109/00365521.2012.677952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
325 Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, Kim CW, Cho J, Suh BS, Cho YK, Chung EC, Shin H, Kim YS. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63:1229-1237. [PMID: 26385766 DOI: 10.1016/j.jhep.2015.07.010] [Cited by in Crossref: 96] [Cited by in F6Publishing: 98] [Article Influence: 16.0] [Reference Citation Analysis]
326 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6(5): 263-273 [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 11.0] [Reference Citation Analysis]
327 Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26 Suppl 1:163-172. [PMID: 21199528 DOI: 10.1111/j.1440-1746.2010.06548.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 11.0] [Reference Citation Analysis]
328 Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012;56:769-75. [PMID: 22378017 DOI: 10.1002/hep.25670] [Cited by in Crossref: 249] [Cited by in F6Publishing: 240] [Article Influence: 27.7] [Reference Citation Analysis]
329 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
330 Sanyal AJ, Miller V. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. Gastroenterology 2016;150:1723-7. [PMID: 26924092 DOI: 10.1053/j.gastro.2016.02.044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
331 Vanni E, Mezzabotta L, Bugianesi E. NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really? Curr Hepatology Rep 2014;13:113-8. [DOI: 10.1007/s11901-014-0225-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
332 Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919-928. [PMID: 26651253 DOI: 10.1016/j.bpg.2015.09.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 12.3] [Reference Citation Analysis]
333 Chang Y, Noh JW, Cheon JY, Kim Y, Kwon YD, Ryu S. Self-rated health and risk of incident non-alcoholic fatty liver disease: A cohort study. Sci Rep 2020;10:3826. [PMID: 32123241 DOI: 10.1038/s41598-020-60823-8] [Reference Citation Analysis]
334 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 37.0] [Reference Citation Analysis]
335 Siriwardana RC, Niriella MA, Dassanayake A, Ediriweera D, Gunetilleke B, Sivasundaram T, de Silva J. Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma. Liver Cancer 2017;6:307-12. [PMID: 29234634 DOI: 10.1159/000477266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
336 van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen H, Jansen PL, Ijzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. European Journal of Gastroenterology & Hepatology 2016;28:352-9. [DOI: 10.1097/meg.0000000000000527] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
337 Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
338 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1697] [Article Influence: 180.6] [Reference Citation Analysis]
339 Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;. [PMID: 32997882 DOI: 10.1111/liv.14675] [Cited by in Crossref: 46] [Cited by in F6Publishing: 55] [Article Influence: 46.0] [Reference Citation Analysis]
340 van Meer S, van Erpecum KJ, Sprengers D, Klümpen HJ, Jansen PL, Ijzermans JN, Siersema PD, de Man RA, Verheij J. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28:955-62. [PMID: 27196679 DOI: 10.1097/MEG.0000000000000641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
341 Marengo A, Jouness RI, Bugianesi E. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clin Liver Dis 2016;20:313-24. [PMID: 27063271 DOI: 10.1016/j.cld.2015.10.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
342 Matsuda Y, Wakai T, Hirose Y, Osawa M, Fujimaki S, Kubota M. p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci 2013;14:23499-515. [PMID: 24351862 DOI: 10.3390/ijms141223499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
343 Cauchy F, Mebarki M, Leporq B, Laouirem S, Albuquerque M, Lambert S, Bourgoin P, Soubrane O, Van Beers BE, Faivre S, Bedossa P, Paradis V. Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clin Sci (Lond) 2017;131:27-36. [PMID: 27803295 DOI: 10.1042/CS20160438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
344 Fukushima H, Kono H, Hirayama K, Akazawa Y, Nakata Y, Wakana H, Fujii H. Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease. Clin Exp Gastroenterol 2020;13:305-14. [PMID: 32922061 DOI: 10.2147/CEG.S248635] [Reference Citation Analysis]
345 Mao Y, Du S, Ba J, Li F, Yang H, Lu X, Sang X, Li S, Che L, Tong J. Using Dynamic 99mT c-GSA SPECT/CT fusion images for hepatectomy planning and postoperative liver failure prediction. Ann Surg Oncol. 2015;22:1301-1307. [PMID: 25294018 DOI: 10.1245/s10434-014-4117-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
346 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 286] [Article Influence: 134.0] [Reference Citation Analysis]
347 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T. Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan. BMC Res Notes. 2011;4:341. [PMID: 21906297 DOI: 10.1186/1756-0500-4-341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
348 Lucey MR. Alcohol-Associated Cirrhosis. Clin Liver Dis 2019;23:115-26. [PMID: 30454826 DOI: 10.1016/j.cld.2018.09.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
349 Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999-2014.e1. [DOI: 10.1053/j.gastro.2019.11.312] [Cited by in Crossref: 428] [Cited by in F6Publishing: 423] [Article Influence: 428.0] [Reference Citation Analysis]
350 Yu J, Shi X, Yang C, Bullova P, Hong CS, Nesvick CL, Dmitriev P, Pacak K, Zhuang Z, Cao H, Li L. A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. Aging (Albany NY) 2020;12:5781-91. [PMID: 32235007 DOI: 10.18632/aging.102967] [Reference Citation Analysis]
351 D'Avola D, Labgaa I, Villanueva A. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis (Hoboken) 2016;8:100-4. [PMID: 31041073 DOI: 10.1002/cld.579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
352 Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS 2019;33:1105-15. [PMID: 31045941 DOI: 10.1097/QAD.0000000000002161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
353 Takamura M, Kanefuji T, Suda T, Yokoo T, Kamimura H, Tsuchiya A, Kamimura K, Tamura Y, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease : HCC risk assessment by VTTQ. Hepatol Int 2014;8:240-9. [PMID: 26202505 DOI: 10.1007/s12072-014-9517-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
354 Yun KE, Nam GE, Lim J, Park HS, Chang Y, Jung HS, Kim CW, Ko BJ, Chung EC, Shin H, Ryu S. Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. PLoS One. 2016;11:e0158710. [PMID: 27420035 DOI: 10.1371/journal.pone.0158710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
355 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 228.6] [Reference Citation Analysis]
356 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 222] [Article Influence: 78.3] [Reference Citation Analysis]
357 Tschida BR, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Sarver AL, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, Keng VW, Largaespada DA. Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. Cancer Res 2017;77:6576-88. [PMID: 28993411 DOI: 10.1158/0008-5472.CAN-17-2281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
358 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Cassinotto C, Aubé C, Dohan A. Diagnosis of hepatocellular carcinoma: An update on international guidelines. Diagn Interv Imaging 2017;98:379-91. [PMID: 28395852 DOI: 10.1016/j.diii.2017.01.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
360 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
361 Armstrong MJ, Mellinger JL, Trivedi PJ. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. Am J Gastroenterol 2018;113:1437-9. [PMID: 30166633 DOI: 10.1038/s41395-018-0237-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9. [DOI: 10.1007/s12072-015-9679-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
363 Hagiwara S, Kudo M, Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T. Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. Hepatol Res 2012;42:394-400. [PMID: 22296598 DOI: 10.1111/j.1872-034X.2011.00932.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
364 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
365 Buyco DG, Martin J, Jeon S, Hooks R, Lin C, Carr R. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021; 27(1): 1-18 [PMID: 33505147 DOI: 10.3748/wjg.v27.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
366 Zheng Y, Zhong X, Huang Y, Zheng C. HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. Annals of Hepatology 2018;17:511-8. [DOI: 10.5604/01.3001.0011.7396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
367 Ju H, Han K, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy: Transgenic mouse models generated by hydrodynamic transfection. Int J Cancer 2016;138:1601-8. [DOI: 10.1002/ijc.29703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
368 Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018;68:251-67. [DOI: 10.1016/j.jhep.2017.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
369 Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, Little AF. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61:34-39. [PMID: 27558976 DOI: 10.1111/1754-9485.12513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
370 Seitz HK, Stickel F. Ethanol and Hepatocarcinogenesis. In: Watson RR, Preedy VR, Zibadi S, editors. Alcohol, Nutrition, and Health Consequences. Totowa: Humana Press; 2013. pp. 411-27. [DOI: 10.1007/978-1-62703-047-2_32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
371 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
372 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
373 Cho H, Chang Y, Lee JH, Cho YY, Nam JY, Lee YB, Lee DH, Cho EJ, Yu SJ, Kim YJ, Lee JM, Yoon JH. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. J Clin Gastroenterol 2020;54:633-41. [PMID: 31033805 DOI: 10.1097/MCG.0000000000001217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
374 Kawaguchi T, Nakano D, Koga H, Torimura T. Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model. Liver Cancer 2019;8:359-72. [PMID: 31768345 DOI: 10.1159/000491763] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
375 Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria : A randomized trial: Phyllanthus for NASH. J Gastroenterol Hepatol 2013;28:57-62. [DOI: 10.1111/j.1440-1746.2012.07286.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
376 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012;56:2172-9. [PMID: 22707355 DOI: 10.1002/hep.25887] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
377 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 505] [Article Influence: 59.6] [Reference Citation Analysis]
378 Benbow JH, Thompson KJ, Cope HL, Brandon-Warner E, Culberson CR, Bossi KL, Li T, Russo MW, Gersin KS, McKillop IH, deLemos AS, Schrum LW. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling. Am J Pathol. 2016;186:145-158. [PMID: 26603137 DOI: 10.1016/j.ajpath.2015.09.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
379 Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 2021;56:951-63. [PMID: 34533632 DOI: 10.1007/s00535-021-01796-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Kimura K, Nakayama M, Naito I, Komiyama T, Ichimura K, Asano H, Tsukuda K, Ohtsuka A, Oohashi T, Miyoshi S, Ninomiya Y. Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis. Int J Clin Oncol 2016;21:302-9. [DOI: 10.1007/s10147-015-0888-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
381 Nasr P, Iredahl F, Dahlström N, Rådholm K, Henriksson P, Cedersund G, Dahlqvist Leinhard O, Ebbers T, Alfredsson J, Carlhäll CJ, Lundberg P, Kechagias S, Ekstedt M. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol 2021;21:180. [PMID: 33879084 DOI: 10.1186/s12876-021-01763-z] [Reference Citation Analysis]
382 Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, Ng IO, Wong CC. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis. 2018;7:44. [PMID: 29799025 DOI: 10.1038/s41389-018-0052-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
383 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
384 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
385 Amann VR, Santos LPD, Gigante DP. [Association of excess weight and obesity and mortality in Brazilian state capitals and Argentine provinces]. Cad Saude Publica 2019;35:e00192518. [PMID: 31800787 DOI: 10.1590/0102-311X00192518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
386 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
387 Tortora R, Rispo A, Alisi A, Imperatore N, Crudele A, Ferretti F, Nobili V, Miele L, Gerbino N, Caporaso N, Morisco F. PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. Nutrients 2018;10:E1239. [PMID: 30189691 DOI: 10.3390/nu10091239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
388 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
389 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
390 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 69] [Article Influence: 11.9] [Reference Citation Analysis]
391 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 244] [Article Influence: 49.6] [Reference Citation Analysis]
392 Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1-17. [PMID: 25444466 DOI: 10.1016/j.soc.2014.09.001] [Cited by in Crossref: 168] [Cited by in F6Publishing: 164] [Article Influence: 24.0] [Reference Citation Analysis]
393 Ghadieh HE, Muturi HT, Najjar SM. Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. J Diabetes Treat 2017;2017. [PMID: 29431170 DOI: 10.29011/2574.7568.000033] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
394 Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. J Med Ultrasound 2019;27:19-25. [PMID: 31031531 DOI: 10.4103/JMU.JMU_53_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
395 Macías J, Real LM, Rivero-Juárez A, Merchante N, Camacho A, Neukam K, Rivero A, Mancebo M, Pineda JA. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med 2016;17:766-73. [PMID: 27028546 DOI: 10.1111/hiv.12384] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
396 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
397 Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim H, Ahn J, Jung H, Yun KE, Kim S, Sung K, Sohn CI, Shin H, Wild SH, Byrne CD. Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. Hepatology 2020;71:861-73. [DOI: 10.1002/hep.30867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
398 Jung JY, Shim JJ, Park SK, Ryoo JH, Choi JM, Oh IH, Jung KW, Cho H, Ki M, Won YJ, Oh CM. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int 2019;13:222-33. [PMID: 30182166 DOI: 10.1007/s12072-018-9892-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
399 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
400 Pisano G, Lombardi R, Fracanzani AL. Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. Int J Mol Sci 2016;17:E675. [PMID: 27164079 DOI: 10.3390/ijms17050675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
401 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 32] [Article Influence: 0.8] [Reference Citation Analysis]
402 Phisalprapa P, Prasitwarachot R, Kositamongkol C, Hengswat P, Srivanichakorn W, Washirasaksiri C, Treeprasertsuk S, Charatcharoenwitthaya P, Chaiyakunapruk N. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol 2021;21:135. [PMID: 33765931 DOI: 10.1186/s12876-021-01720-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
403 Gavilán JC, Ojeda G, Arnedo R, Puerta S. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C. European Journal of Internal Medicine 2013;24:846-51. [DOI: 10.1016/j.ejim.2013.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
404 Siriwardana RC, Liyanage CAH, Gunetilleke B, Niriella MA, de Silva J, Dassanayake AS, Jayatunge SP. Diffuse-Type Hepatoma: A Grave Prognostic Marker. Gastrointest Tumors 2017;4:20-7. [PMID: 29071261 DOI: 10.1159/000460249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
405 Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol 2018;113:1475-83. [PMID: 29535416 DOI: 10.1038/s41395-018-0041-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
406 Basaranoglu M, Najjar SM, Demirbag AE, Senturk H. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list. World J Hepatol 2016; 8(7): 376-384 [PMID: 26981175 DOI: 10.4254/wjh.v8.i7.376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
407 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
408 Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011;46:63-9. [DOI: 10.1007/s00535-010-0311-8] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 13.8] [Reference Citation Analysis]
409 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
410 Marks P, Williams R. Calorie and alcohol consumption in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2012;24:527-530. [PMID: 22343784 DOI: 10.1097/meg.0b013e3283514edb] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
411 Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8393-8406 [PMID: 25024597 DOI: 10.3748/wjg.v20.i26.8393] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
412 Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, Mckillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology 2015;99:596-610. [DOI: 10.1016/j.yexmp.2015.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
413 Liu K, Wong VW, Lau K, Liu SD, Tse Y, Yip TC, Kwok R, Chan AY, Chan HL, Wong GL. Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. American Journal of Gastroenterology 2017;112:1812-23. [DOI: 10.1038/ajg.2017.389] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
414 Venepalli NK, Modayil MV, Berg SA, Nair TD, Parepally M, Rajaram P, Gaba RC, Bui JT, Huang Y, Cotler SJ. Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites. World J Hepatol 2017; 9(7): 391-400 [PMID: 28321275 DOI: 10.4254/wjh.v9.i7.391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
415 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
416 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
417 Schulz PO, Ferreira FG, Nascimento MFA, Vieira A, Ribeiro MA, David AI, Szutan LA. Association of nonalcoholic fatty liver disease and liver cancer. World J Gastroenterol 2015; 21(3): 913-918 [PMID: 25624725 DOI: 10.3748/wjg.v21.i3.913] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
418 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
419 Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;133:1776-1783. [PMID: 23404222 DOI: 10.1002/ijc.28105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
420 Lazo M, Rubin J, Clark JM, Coresh J, Schneider AL, Ndumele C, Hoogeveen RC, Ballantyne CM, Selvin E. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015;62:841-847. [PMID: 25433159 DOI: 10.1016/j.jhep.2014.11.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
421 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
422 Appel-da-Silva MC, Miozzo SADS, Dossin IA, Tovo CV, Branco F, Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol 2016; 22(46): 10219-10225 [PMID: 28028370 DOI: 10.3748/wjg.v22.i46.10219] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
423 Zhang L, She ZG, Li H, Zhang XJ. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond) 2020;134:1775-99. [PMID: 32677680 DOI: 10.1042/CS20200446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
424 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
425 Alkhouri N, Kohli R, Feldstein AE. Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints. Hepatol Commun 2019;3:1563-70. [PMID: 31832567 DOI: 10.1002/hep4.1449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
426 Dai N, Zou Y, Zhu L, Wang HF, Dai MG. Antioxidant properties of proanthocyanidins attenuate carbon tetrachloride (CCl4)-induced steatosis and liver injury in rats via CYP2E1 regulation. J Med Food 2014;17:663-9. [PMID: 24712752 DOI: 10.1089/jmf.2013.2834] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
427 Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344-353. [PMID: 21520200 DOI: 10.1002/hep.24376] [Cited by in Crossref: 431] [Cited by in F6Publishing: 406] [Article Influence: 43.1] [Reference Citation Analysis]
428 Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Kim KJ, Han K. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2017;62:2150-8. [DOI: 10.1007/s10620-017-4592-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
429 Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891. [PMID: 22102439 DOI: 10.1136/bmj.d6891] [Cited by in Crossref: 231] [Cited by in F6Publishing: 218] [Article Influence: 23.1] [Reference Citation Analysis]
430 Flores A, Asrani SK. Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade? Am J Gastroenterol 2016;111:995-6. [PMID: 27356823 DOI: 10.1038/ajg.2016.220] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
431 London WT, McGlynn KA. Can propranalol prevent hepatocellular carcinoma? Cancer Prev Res (Phila) 2012;5:989-91. [PMID: 22869451 DOI: 10.1158/1940-6207.CAPR-12-0247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
432 Okanoue T, Yasui K, Itoh Y. Non-Alcoholic Fatty Liver Disease in Japan. In: Farrell GC, Mccullough AJ, Day CP, editors. Non-Alcoholic Fatty Liver Disease. Oxford: Wiley-Blackwell; 2013. pp. 217-27. [DOI: 10.1002/9781118556153.ch19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Kew MC. Obesity as a cause of hepatocellular carcinoma. Annals of Hepatology 2015;14:299-303. [DOI: 10.1016/s1665-2681(19)31267-0] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
434 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol 2020;35:1579-89. [PMID: 31975453 DOI: 10.1111/jgh.14989] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
435 Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, Chaiyakunapruk N. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2017;96:e6585. [PMID: 28445256 DOI: 10.1097/MD.0000000000006585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
436 Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Chiba T, Kanai F, Yokosuka O, Yamaguchi T. Natural history of postvascular-phase iso-enhanced lesions on the sonogram in chronic liver diseases. J Gastroenterol Hepatol 2014;29:165-72. [PMID: 24224484 DOI: 10.1111/jgh.12449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
437 Lodhi M, Amin J, Eswaran S. Role of alcohol in nonalcoholic steatohepatitis: Rush university (Con) patients with nonalcoholic steatohepatitis should be abstinent from alcohol use. Clin Liver Dis (Hoboken) 2018;11:39-42. [PMID: 30992785 DOI: 10.1002/cld.669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Tran NL, Sitia G. New players in non-alcoholic fatty liver disease induced carcinogenesis: lipid dysregulation impairs liver immune surveillance. Hepatobiliary Surg Nutr 2016;5:511-4. [PMID: 28124011 DOI: 10.21037/hbsn.2016.11.08] [Reference Citation Analysis]
439 Borzio M, Dionigi E, Vitale A, Rossini A, Marignani M, Fornari F, Vicari S, De Sio I, Farinati F, Bertolini E, Oliveri F, Leandro G, Francica G, Mitra M, Omazzi B, Boccia S, Salmi A, Toldi A, Sacco R. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. Liver Int 2017;37:1184-92. [DOI: 10.1111/liv.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
440 Goceri E, Shah ZK, Layman R, Jiang X, Gurcan MN. Quantification of liver fat: A comprehensive review. Comput Biol Med 2016;71:174-89. [PMID: 26945465 DOI: 10.1016/j.compbiomed.2016.02.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
441 Shearn CT, Petersen DR. Understanding the Tumor Suppressor PTEN in Chronic Alcoholism and Hepatocellular Carcinoma. In: Vasiliou V, Zakhari S, Seitz HK, Hoek JB, editors. Biological Basis of Alcohol-Induced Cancer. Cham: Springer International Publishing; 2015. pp. 173-84. [DOI: 10.1007/978-3-319-09614-8_10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
442 Rinella ME. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology 2011;54:1118-20. [DOI: 10.1002/hep.24634] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
443 Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52-64. [PMID: 30360031 DOI: 10.3350/cmh.2018.0040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
444 Sakamoto H, Miyanishi K, Tanaka S, Ito R, Hamaguchi K, Sakurada A, Sato M, Kubo T, Osuga T, Murase K, Takada K, Nakabeppu Y, Kobune M, Kato J. MUTYH is associated with hepatocarcinogenesis in a non-alcoholic steatohepatitis mouse model. Sci Rep 2021;11:3599. [PMID: 33574380 DOI: 10.1038/s41598-021-83138-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
445 Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front Med (Lausanne) 2020;7:448. [PMID: 32974366 DOI: 10.3389/fmed.2020.00448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
446 Sekimoto T, Maruyama H, Kiyono S, Kondo T, Shimada T, Ishibashi H, Takahashi M, Yokosuka O, Yamaguchi T. Hepatic filling rate of a microbubble agent: a novel predictor of long-term outcomes in patients with cirrhosis. Ultrasound Med Biol 2014;40:2082-8. [PMID: 25018029 DOI: 10.1016/j.ultrasmedbio.2014.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
447 Rim MY, Kwon OS, Ha M, Kim JS, Ko KI, Kim DK, Jang PK, Han JY, Park PH, Jung YK, Choi DJ, Kim YS, Kim JH. [Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma]. Korean J Gastroenterol 2014;63:292-8. [PMID: 24870301 DOI: 10.4166/kjg.2014.63.5.292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
448 Teufel U, Peccerella T, Engelmann G, Bruckner T, Flechtenmacher C, Millonig G, Stickel F, Hoffmann GF, Schirmacher P, Mueller S, Bartsch H, Seitz HK. Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr 2015;4:426-35. [PMID: 26734629 DOI: 10.3978/j.issn.2304-3881.2015.12.03] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
449 Santoro N, Caprio S, Feldstein AE. Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clin Lipidol 2013;8:411-8. [PMID: 26405460 DOI: 10.2217/clp.13.39] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
450 Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. J Gastrointest Surg 2014;18:2136-48. [DOI: 10.1007/s11605-014-2667-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
451 Dhillon A, Steadman RH. Liver Diseases. Anesthesia and Uncommon Diseases. Elsevier; 2012. pp. 162-214. [DOI: 10.1016/b978-1-4377-2787-6.00005-x] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
452 Kim TH, Jeong CW, Jun HY, Lee C, Noh S, Kim JE, Kim S, Yoon KH. Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. Sci Rep 2019;9:15002. [PMID: 31628409 DOI: 10.1038/s41598-019-51302-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
453 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
454 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
455 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
456 Hydes TJ, Ravi S, Loomba R, E Gray M. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 2020;26:383-400. [PMID: 32674529 DOI: 10.3350/cmh.2020.0067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
457 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
459 Fatima S, Lee NP, Luk JM. Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol 2011; 2(8): 311-325 [PMID: 21876852 DOI: 10.5306/wjco.v2.i8.311] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
460 Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016;51:1022-1030. [PMID: 26874844 DOI: 10.1007/s00535-016-1178-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
461 Acharya UR, Fujita H, Sudarshan VK, Mookiah MRK, Koh JE, Tan JH, Hagiwara Y, Chua CK, Junnarkar SP, Vijayananthan A, Ng KH. An integrated index for identification of fatty liver disease using radon transform and discrete cosine transform features in ultrasound images. Information Fusion 2016;31:43-53. [DOI: 10.1016/j.inffus.2015.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 6.2] [Reference Citation Analysis]
462 Hayashi T, Saitoh S, Fukuzawa K, Tsuji Y, Takahashi J, Kawamura Y, Akuta N, Kobayashi M, Ikeda K, Fujii T, Miyati T, Kumada H. Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2017;11:674-83. [PMID: 28651300 DOI: 10.5009/gnl16440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
463 Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, Sulpice T, Martinez LO. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2019;317:G508-17. [PMID: 31460789 DOI: 10.1152/ajpgi.00139.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
464 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 16.8] [Reference Citation Analysis]
465 Uchida H, Iwashita Y, Saga K, Takayama H, Watanabe K, Endo Y, Yada K, Ohta M, Inomata M. Benefit of laparoscopic liver resection in high body mass index patients. World J Gastroenterol 2016; 22(10): 3015-3022 [PMID: 26973397 DOI: 10.3748/wjg.v22.i10.3015] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
466 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29] [Cited by in Crossref: 642] [Cited by in F6Publishing: 412] [Article Influence: 80.3] [Reference Citation Analysis]
467 Cheng BC, Yen YH, Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB, Hu TH. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep 2017;7:46458. [PMID: 28422172 DOI: 10.1038/srep46458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
468 Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16. [PMID: 21688282 DOI: 10.1002/hep.24491] [Cited by in Crossref: 305] [Cited by in F6Publishing: 281] [Article Influence: 30.5] [Reference Citation Analysis]
469 Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5. [PMID: 27239288 DOI: 10.12688/f1000research.6946.1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
470 Shirazi F, Wang J, Wong RJ. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. J Clin Exp Hepatol 2020;10:30-6. [PMID: 32025164 DOI: 10.1016/j.jceh.2019.06.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
471 Corey KE, Misdraji J, Gelrud L, King LY, Zheng H, Malhotra A, Chung RT. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci 2015;60:2523-8. [PMID: 25840922 DOI: 10.1007/s10620-015-3650-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
472 Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2013;35:191-202. [PMID: 22945457 DOI: 10.1007/s00281-012-0336-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
473 Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84. [PMID: 34453963 DOI: 10.1016/j.jhep.2021.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
474 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 22.0] [Reference Citation Analysis]
475 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
476 Ukawa S, Tamakoshi A, Murakami Y, Kiyohara Y, Yamada M, Nagai M, Satoh A, Miura K, Ueshima H, Okamura T, EPOCH-JAPAN Research Group. Pooled Analysis of the Associations between Body Mass Index, Total Cholesterol, and Liver Cancer-related Mortality in Japan. Asian Pac J Cancer Prev 2018;19:2089-95. [PMID: 30139206 DOI: 10.22034/APJCP.2018.19.8.2089] [Reference Citation Analysis]
477 Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, Nistor GI, Cao W, Chen C, Dillman RO. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111:862-7. [PMID: 25873455 DOI: 10.1002/jso.23897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
478 Bellanti F, Villani R, Facciorusso A, Vendemiale G, Serviddio G. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radical Biology and Medicine 2017;111:173-85. [DOI: 10.1016/j.freeradbiomed.2017.01.023] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 15.8] [Reference Citation Analysis]
479 Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects. Diagn Interv Imaging. 2014;95:705-708. [PMID: 24768454 DOI: 10.1016/j.diii.2014.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
480 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
481 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
482 Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9:563-582. [PMID: 33083281 DOI: 10.1159/000508568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
483 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
484 Kedar Mukthinuthalapati VVP, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, Abou-Alfa GK. Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Glob Oncol 2021;7:756-66. [PMID: 34043413 DOI: 10.1200/GO.20.00425] [Reference Citation Analysis]
485 Wong VW, Wong GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology 2013;12:256-62. [DOI: 10.1016/s1665-2681(19)31364-x] [Cited by in Crossref: 158] [Article Influence: 19.8] [Reference Citation Analysis]
486 Sasdelli AS, Brodosi L, Marchesini G. NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Curr Hepatology Rep 2016;15:103-12. [DOI: 10.1007/s11901-016-0297-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
487 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
488 Chang Y, Jung H, Yun KE, Cho J, Cho YK, Ryu S. Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population. American Journal of Gastroenterology 2013;108:1861-8. [DOI: 10.1038/ajg.2013.349] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 12.9] [Reference Citation Analysis]
489 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 167] [Article Influence: 27.0] [Reference Citation Analysis]
490 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
491 You N, Li J, Huang X, Wu K, Tang Y, Wang L, Li H, Mi N, Zheng L. COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. Biomed Pharmacother 2017;88:653-7. [PMID: 28142122 DOI: 10.1016/j.biopha.2017.01.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
492 Magistri P, Leonard SY, Tang CM, Chan JC, Lee TE, Sicklick JK. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. J Surg Res 2014;187:377-85. [PMID: 24439425 DOI: 10.1016/j.jss.2013.12.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
493 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 124] [Article Influence: 25.8] [Reference Citation Analysis]
494 Siriwardana RC, Niriella MA, Dassanayake AS, Liyanage C, Gunathilaka B, Jayathunge S, de Silva HJ. Clinical characteristics and outcome of hepatocellular carcinoma in alcohol related and cryptogenic cirrhosis: a prospective study. Hepatobiliary Pancreat Dis Int 2015;14:401-5. [PMID: 26256085 DOI: 10.1016/s1499-3872(15)60343-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
495 Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, Seki E, Harismendy O, Shalapour S, Karin M, Carter H, Font-Burgada J. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2018;115:E9879-88. [PMID: 30287485 DOI: 10.1073/pnas.1811029115] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
496 Araújo OC, Rosa AS, Fernandes A, Niel C, Villela-Nogueira CA, Pannain V, Araujo NM. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients. PLoS One 2016;11:e0153796. [PMID: 27078152 DOI: 10.1371/journal.pone.0153796] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
497 Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H. (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus 2013;2:690. [PMID: 25674420 DOI: 10.1186/2193-1801-2-690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
498 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
499 Nakamura Y, Mizuguchi T, Tanimizu N, Ichinohe N, Ooe H, Kawamoto M, Meguro M, Hirata K, Mitaka T. Preoperative hepatocyte transplantation improves the survival of rats with nonalcoholic steatohepatitis-related cirrhosis after partial hepatectomy. Cell Transplant. 2014;23:1243-1254. [PMID: 25330059 DOI: 10.3727/096368913x668645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
500 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
501 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
502 Duarte SMB, Stefano JT, Vanni DS, Carrilho FJ, Oliveira CPMS. IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Arq Gastroenterol 2019;56:431-9. [PMID: 31721969 DOI: 10.1590/S0004-2803.201900000-67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
503 Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Grigorean G, Li L, Liu S, Singal AG, Parikh ND, Lubman DM. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. J Proteome Res. 2020;19:3452-3466. [PMID: 32412768 DOI: 10.1021/acs.jproteome.0c00270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
504 Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016;65:1151-60. [DOI: 10.1016/j.metabol.2016.01.010] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 16.8] [Reference Citation Analysis]
505 Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483-491. [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
506 Klein T, Fujii M, Sandel J, Shibazaki Y, Wakamatsu K, Mark M, Yoneyama H. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2014;47:137-149. [PMID: 24048504 DOI: 10.1007/s00795-013-0053-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
507 Bonner K, Heimbach JK. Obesity management in the liver transplant recipient: the role of bariatric surgery. Current Opinion in Organ Transplantation 2018;23:244-9. [DOI: 10.1097/mot.0000000000000513] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
508 Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230-1237. [PMID: 21748549 DOI: 10.1007/s00535-011-0431-9] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 9.1] [Reference Citation Analysis]
509 Seitz HK, Neuman MG. The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology. J Clin Med 2021;10:858. [PMID: 33669694 DOI: 10.3390/jcm10040858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
510 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 238] [Article Influence: 27.2] [Reference Citation Analysis]
511 Han MH, Lee JH, Kim G, Lee E, Lee YR, Jang SY, Lee HW, Chun JM, Han YS, Yoon JS, Kang MK, Lee WK, Kweon YO, Tak WY, Park SY, Park JG, Hur K. Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Genes (Basel) 2020;11:E545. [PMID: 32413995 DOI: 10.3390/genes11050545] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
512 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 49.0] [Reference Citation Analysis]
513 Huber Y, Bierling F, Labenz C, Koch S, Schmidtmann I, Kloeckner R, Schotten S, Huber T, Lang H, Woerns MA, Galle PR, Weinmann A, Weinmann-Menke J. Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort. BMC Cancer 2018;18:774. [PMID: 30064393 DOI: 10.1186/s12885-018-4677-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
514 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
515 Heimbach J. Debate: A bridge too far--liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transpl. 2014;20 Suppl 2:S32-S37. [PMID: 25155244 DOI: 10.1002/lt.23980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
516 Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862-869. [PMID: 31597206 DOI: 10.1111/jgh.14867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
517 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 185] [Article Influence: 41.2] [Reference Citation Analysis]
518 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 13.8] [Reference Citation Analysis]
519 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med 2014;8:759-62. [PMID: 25120595 DOI: 10.3892/etm.2014.1798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
520 Wainwright P, Scorletti E, Byrne CD. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Curr Diab Rep 2017;17. [DOI: 10.1007/s11892-017-0851-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
521 Healy ME, Chow JD, Byrne FL, Breen DS, Leitinger N, Li C, Lackner C, Caldwell SH, Hoehn KL. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol. 2015;62:599-606. [PMID: 25450719 DOI: 10.1016/j.jhep.2014.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
522 Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014;21:758-66. [PMID: 24006095 DOI: 10.1245/s10434-013-3254-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
523 Shibasaki Y, Horikawa M, Ikegami K, Kiuchi R, Takeda M, Hiraide T, Morita Y, Konno H, Takeuchi H, Setou M, Sakaguchi T. Stearate-to-palmitate ratio modulates endoplasmic reticulum stress and cell apoptosis in non-B non-C hepatoma cells. Cancer Sci 2018;109:1110-20. [PMID: 29427339 DOI: 10.1111/cas.13529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
524 Stepanova M, Clement S, Wong R, Saab S, Ahmed A, Younossi ZM. Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. Clin Diabetes 2017;35:79-83. [PMID: 28442821 DOI: 10.2337/cd16-0018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
525 Huang Y, Wan T, Pang N, Zhou Y, Jiang X, Li B, Gu Y, Huang Y, Ye X, Lian H, Zhang Z, Yang L. Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway. J Cell Physiol 2019;234:21224-34. [DOI: 10.1002/jcp.28728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
526 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, Kudo M. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84 Suppl 1:43-49. [PMID: 22156485 DOI: 10.1159/000333212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
527 Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314-1321. [PMID: 23752878 DOI: 10.1038/ajg.2013.160] [Cited by in Crossref: 201] [Cited by in F6Publishing: 184] [Article Influence: 25.1] [Reference Citation Analysis]
528 Macías J, González J, Tural C, Ortega-González E, Pulido F, Rubio R, Cifuentes C, Díaz-Menéndez M, Jou A, Rubio P, Burgos A, Pineda JA. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 2014;28:1279-87. [PMID: 24614088 DOI: 10.1097/QAD.0000000000000248] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
529 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 107.6] [Reference Citation Analysis]
530 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
531 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
532 Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, Chim AM, Yeung DK, Yu J, Chu WC. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther. 2012;36:1057-1066. [PMID: 23066946 DOI: 10.1111/apt.12091] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
533 Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35:2203-2217. [PMID: 26123841 DOI: 10.1111/liv.12903] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
534 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471. [PMID: 21538440 DOI: 10.1002/hep.24397] [Cited by in Crossref: 338] [Cited by in F6Publishing: 357] [Article Influence: 33.8] [Reference Citation Analysis]
535 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
536 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
537 Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, De Vincentis A, Dell'Unto C, Vorini F, Morini S, Riva E, Picardi A. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016;51:967-73. [PMID: 27150500 DOI: 10.3109/00365521.2016.1161066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
538 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
539 Liu Y, Patman G, Leathart J, Piguet A, Burt A, Dufour J, Day C, Daly A, Reeves H, Anstee Q. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology 2014;61:75-81. [DOI: 10.1016/j.jhep.2014.02.030] [Cited by in Crossref: 260] [Cited by in F6Publishing: 246] [Article Influence: 37.1] [Reference Citation Analysis]
540 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol 2017; 9(11): 533-543 [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 19.8] [Reference Citation Analysis]
541 Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. Oncotarget 2018;9:28638-51. [PMID: 29983886 DOI: 10.18632/oncotarget.25587] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
542 Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, Kwan CT, Lam H, Limquiaco J, Chim AM, Yu C, Chan HL. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study: Hepatology. Hepatology 2016;63:754-63. [DOI: 10.1002/hep.28253] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
543 Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol 2014;45:834-43. [PMID: 24656094 DOI: 10.1016/j.humpath.2013.12.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
544 Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. Gastroenterology 2017; 153: 1006-1017. e5. [PMID: 28711626 DOI: 10.1053/j.gastro.2017.07.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 15.5] [Reference Citation Analysis]
545 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 28.5] [Reference Citation Analysis]
546 Önnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol. 2014;49:1111-1118. [PMID: 24990583 DOI: 10.3109/00365521.2014.934911] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
547 Song H, Sun N, Lin L, Wei S, Zeng K, Liu W, Wang C, Zhong X, Wang M, Wang S, Zhou B, Lv C, Liu W, Zhao Y. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma. Cancer Sci 2020;111:3665-78. [PMID: 32745318 DOI: 10.1111/cas.14595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
548 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 135] [Article Influence: 16.9] [Reference Citation Analysis]
549 Fardet A, Martin JF, Chardigny JM. Thermal and refining processes, not fermentation, tend to reduce lipotropic capacity of plant-based foods. Food Funct 2011;2:483-504. [PMID: 21842076 DOI: 10.1039/c1fo10041f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
550 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020; 26(28): 4018-4035 [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
551 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
552 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
553 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 195] [Article Influence: 35.5] [Reference Citation Analysis]
554 Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol 2021;19:136-145.e6. [PMID: 32389886 DOI: 10.1016/j.cgh.2020.04.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
555 Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice. Am J Pathol 2020;190:68-81. [PMID: 31610178 DOI: 10.1016/j.ajpath.2019.09.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
556 Bakulin IG, Sandler YG, Keyan VA, Rotin DL. [A new non-invasive method for assessing steatosis in chronic liver diseases]. Ter Arkh 2016;88:49-57. [PMID: 27030184 DOI: 10.17116/terarkh201688249-57] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
557 Galicia-Moreno M, Lucano-Landeros S, Monroy-Ramirez HC, Silva-Gomez J, Gutierrez-Cuevas J, Santos A, Armendariz-Borunda J. Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects. Antioxidants (Basel) 2020;9:E980. [PMID: 33066023 DOI: 10.3390/antiox9100980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
558 Elshazly SM. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. European Journal of Pharmacology 2015;748:123-32. [DOI: 10.1016/j.ejphar.2014.12.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
559 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 28.7] [Reference Citation Analysis]
560 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
561 Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients 2021;13:2011. [PMID: 34208122 DOI: 10.3390/nu13062011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
562 Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021;56:261-73. [PMID: 33427937 DOI: 10.1007/s00535-020-01754-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
563 Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533-540. [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 13.7] [Reference Citation Analysis]
564 Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56:3316-3322. [PMID: 21805170 DOI: 10.1007/s10620-011-1836-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
565 Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis 2020;24:611-21. [PMID: 33012448 DOI: 10.1016/j.cld.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
566 Vallet-Pichard A, Parlati L, Pol S. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health]. Presse Med 2019;48:1459-67. [PMID: 31757728 DOI: 10.1016/j.lpm.2019.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
567 Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N, Saito H. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 2018;9:9925-39. [PMID: 29515780 DOI: 10.18632/oncotarget.24066] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
568 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
569 Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, Sotorríos NG, Martínez M, Rodrigo L, Rodríguez M. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol. 2013;11:95-101. [PMID: 22982095 DOI: 10.1016/j.cgh.2012.09.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 9.9] [Reference Citation Analysis]
570 Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011;16:121-36. [PMID: 21352073 DOI: 10.1517/14728214.2011.531700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
571 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
572 Pillai S, Duvvuru S, Bhatnagar P, Foster W, Farmen M, Shankar S, Harris C, Bastyr E, Hoogwerf B, Haupt A. The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro. Pharmacogenomics J 2018;18:487-93. [DOI: 10.1038/tpj.2017.45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
573 Ryu S, Chang Y, Choi Y, Kwon MJ, Kim CW, Yun KE, Jung HS, Kim BK, Kim YJ, Ahn J, Cho YK, Kim KH, Chung EC, Shin H, Cho J. Age at menarche and non-alcoholic fatty liver disease. J Hepatol 2015;62:1164-70. [PMID: 25500721 DOI: 10.1016/j.jhep.2014.11.041] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
574 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5:277-286. [PMID: 25285192 DOI: 10.1136/flgastro-2013-100404] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
575 Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 2015;91:92-101. [PMID: 25655252 DOI: 10.1136/postgradmedj-2013-100404rep] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
576 Zhang XL, Wang WJ, Wang WJ, Cao N. Effectiveness and safety of controlled venous pressure in liver surgery: a systematic review and network meta-analysis. Biomed Res Int 2015;2015:290234. [PMID: 26075222 DOI: 10.1155/2015/290234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
577 Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M. Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma: Data mining of non-HBV/non-HCV-related HCC. Hepatology Research 2011;41:564-71. [DOI: 10.1111/j.1872-034x.2011.00799.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
578 Vreman RA, Goodell AJ, Rodriguez LA, Porco TC, Lustig RH, Kahn JG. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open 2017;7:e013543. [PMID: 28775179 DOI: 10.1136/bmjopen-2016-013543] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
579 Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, Hansen NU, Bay-Jensen AC, Bager CL, Krag A, Blanchard A, Krarup H, Leeming DJ, Schuppan D. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2015;308:G807-30. [PMID: 25767261 DOI: 10.1152/ajpgi.00447.2014] [Cited by in Crossref: 138] [Cited by in F6Publishing: 133] [Article Influence: 23.0] [Reference Citation Analysis]
580 Ryu S, Suh BS, Chang Y, Kwon MJ, Yun KE, Jung HS, Kim CW, Kim BK, Kim YJ, Choi Y, Ahn J, Cho YK, Kim KH, Ahn Y, Park HY, Chung EC, Shin H, Cho J. Menopausal stages and non-alcoholic fatty liver disease in middle-aged women. Eur J Obstet Gynecol Reprod Biol 2015;190:65-70. [PMID: 25988514 DOI: 10.1016/j.ejogrb.2015.04.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
581 Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology 2019;157:590-3. [DOI: 10.1053/j.gastro.2019.05.064] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
582 Underhill GH, Khetani SR. Emerging trends in modeling human liver disease in vitro. APL Bioeng 2019;3:040902. [PMID: 31893256 DOI: 10.1063/1.5119090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
583 Macias J, Rivero-Juarez A, Neukam K, Tellez F, Merino D, Frias M, Merchante N, Rivero A, Pineda JA, Real LM; HEPAVIR study group. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS 2015;29:1927-35. [PMID: 26352879 DOI: 10.1097/QAD.0000000000000799] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
584 Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis: Absence of Cirrhosis in NASH-Derived HCC. Int J Cancer 2011;128:2436-43. [DOI: 10.1002/ijc.25797] [Cited by in Crossref: 290] [Cited by in F6Publishing: 281] [Article Influence: 29.0] [Reference Citation Analysis]
585 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 19.9] [Reference Citation Analysis]
586 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
587 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, Falco L, Caporaso N. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Target Oncol. 2017;12:61-67. [PMID: 27503006 DOI: 10.1007/s11523-016-0454-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
588 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
589 Suwa K, Yamaguchi T, Yoshida K, Murata M, Ichimura M, Tsuneyama K, Seki T, Okazaki K. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. Cancers (Basel) 2020;12:E286. [PMID: 31991602 DOI: 10.3390/cancers12020286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Weiss J, Rau M, Meertens J, Hering I, Reichert L, Kudlich T, Koschker A, Jurowich C, Geier A. Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. Scandinavian Journal of Gastroenterology 2016;51:1263-8. [DOI: 10.1080/00365521.2016.1191084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
591 Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34:834-843. [PMID: 24397349 DOI: 10.1111/liv.12465] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
592 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
593 Kawauchi S, Horibe S, Sasaki N, Tanahashi T, Mizuno S, Hamaguchi T, Rikitake Y. Inhibitory Effects of Sodium Alginate on Hepatic Steatosis in Mice Induced by a Methionine- and Choline-deficient Diet. Mar Drugs 2019;17:E104. [PMID: 30744124 DOI: 10.3390/md17020104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
594 Vansaun MN, Mendonsa AM, Lee Gorden D. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One. 2013;8:e73054. [PMID: 24039859 DOI: 10.1371/journal.pone.0073054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
595 Iida A, Kuranuki S, Yamamoto R, Uchida M, Ohta M, Ichimura M, Tsuneyama K, Masaki T, Seike M, Nakamura T. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. Exp Anim 2019;68:417-28. [PMID: 31155606 DOI: 10.1538/expanim.18-0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
596 Eguchi A, Feldstein AE. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases. Liver Res 2018;2:30-4. [PMID: 30345152 DOI: 10.1016/j.livres.2018.01.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
597 Li Y, Xu A, Jia S, Huang J. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. Oncol Lett 2019;17:4222-8. [PMID: 30988804 DOI: 10.3892/ol.2019.10127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
598 Hsu CC, Kowdley KV. The Effects of Alcohol on Other Chronic Liver Diseases. Clin Liver Dis. 2016;20:581-594. [PMID: 27373618 DOI: 10.1016/j.cld.2016.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
599 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 342] [Article Influence: 40.7] [Reference Citation Analysis]
600 Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. Hepatology 2019;69:564-72. [PMID: 30180285 DOI: 10.1002/hep.30254] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 25.0] [Reference Citation Analysis]
601 Heimbach J. Surgical advances in obese candidates and recipients: Heimbach. Liver Transpl 2016;22:62-7. [DOI: 10.1002/lt.24619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
602 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 212] [Article Influence: 23.3] [Reference Citation Analysis]
603 Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-1090. [PMID: 21618575 DOI: 10.1002/hep.24452] [Cited by in Crossref: 638] [Cited by in F6Publishing: 607] [Article Influence: 70.9] [Reference Citation Analysis]
604 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 1008] [Article Influence: 119.8] [Reference Citation Analysis]
605 Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014;63:607-17. [DOI: 10.1016/j.metabol.2014.01.011] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 14.6] [Reference Citation Analysis]
606 Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Safety of hepatic resection in overweight and obese patients with cirrhosis. British Journal of Surgery 2011;98:1147-54. [DOI: 10.1002/bjs.7516] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
607 Wu S, Tu R, Liu G. Frequency and implication of focal fatty sparing in segmental homogeneous fatty liver at ultrasound. J Med Ultrasonics 2013;40:393-8. [DOI: 10.1007/s10396-013-0440-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
608 Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360-1370. [PMID: 29107284 DOI: 10.1016/j.molmet.2017.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
609 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70:1457-1469. [PMID: 30924946 DOI: 10.1002/hep.30626] [Cited by in Crossref: 163] [Cited by in F6Publishing: 160] [Article Influence: 81.5] [Reference Citation Analysis]
610 Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39:1954-1960. [PMID: 21737566 DOI: 10.1124/dmd.111.040592] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 10.7] [Reference Citation Analysis]
611 Singal AG, Tiro JA, Murphy CC, Marrero JA, McCallister K, Fullington H, Mejias C, Waljee AK, Pechero Bishop W, Santini NO, Halm EA. Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. Hepatology 2019;69:121-30. [PMID: 30070379 DOI: 10.1002/hep.30129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
612 Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-7. [PMID: 24275855 DOI: 10.1097/CCO.0000000000000042] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
613 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
614 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
615 Protopapas AA, Cholongitas E, Chrysavgis L, Tziomalos K. Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no? Ann Gastroenterol 2021;34:476-86. [PMID: 34276185 DOI: 10.20524/aog.2021.0641] [Reference Citation Analysis]
616 Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469-480. [PMID: 23773243 DOI: 10.1016/j.tem.2013.05.004] [Cited by in Crossref: 184] [Cited by in F6Publishing: 169] [Article Influence: 23.0] [Reference Citation Analysis]
617 Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017;112:581-587. [PMID: 28195177 DOI: 10.1038/ajg.2017.5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 25.5] [Reference Citation Analysis]
618 Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41:911-920. [PMID: 21951869 DOI: 10.1111/j.1872-034x.2011.00867.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
619 Zhou C, Zhou J, Han N, Liu Z, Xiao B, Yin J. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats. Int Immunopharmacol. 2015;25:218-228. [PMID: 25661699 DOI: 10.1016/j.intimp.2015.01.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
620 Nazareth S, Leembruggen N, Tuma R, Chen SL, Rao S, Kontorinis N, Cheng W. Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis. Int J Nurs Pract 2016;22 Suppl 2:3-11. [PMID: 27476494 DOI: 10.1111/ijn.12472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
621 Schotten C, Bechmann LP, Manka P, Theysohn J, Dechêne A, El Fouly A, Barbato F, Neumann U, Radünz S, Sydor S, Heider D, Venerito M, Canbay A, Gerken G, Herrmann K, Wedemeyer H, Best J. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer 2019;8:491-504. [PMID: 31799206 DOI: 10.1159/000501484] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
622 Mittal S, Kanwal F, Ying J, Chung R, Sada YH, Temple S, Davila JA, El-Serag HB. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol 2016;65:1148-54. [PMID: 27476765 DOI: 10.1016/j.jhep.2016.07.025] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 15.4] [Reference Citation Analysis]
623 Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018;102:640-647. [PMID: 29319620 DOI: 10.1097/tp.0000000000002043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
624 Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63. [PMID: 28857208 DOI: 10.1111/apt.14261] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
625 Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, Kleemann R, Oka K. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients. Biol Open 2019;8:bio041251. [PMID: 31023717 DOI: 10.1242/bio.041251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
626 Tanaka S, Iimuro Y, Hirano T, Hai S, Suzumura K, Nakamura I, Kondo Y, Fujimoto J. Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis. Surg Today 2013;43:1290-7. [DOI: 10.1007/s00595-013-0706-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
627 Romero-gómez M, Zelber-sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology 2017;67:829-46. [DOI: 10.1016/j.jhep.2017.05.016] [Cited by in Crossref: 360] [Cited by in F6Publishing: 329] [Article Influence: 90.0] [Reference Citation Analysis]
628 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 4.3] [Reference Citation Analysis]
629 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 226.0] [Reference Citation Analysis]
630 VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706-14. [PMID: 28963767 DOI: 10.1111/liv.13603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
631 Povero D, Eguchi A, Niesman IR, Andronikou N, de Mollerat du Jeu X, Mulya A, Berk M, Lazic M, Thapaliya S, Parola M, Patel HH, Feldstein AE. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal 2013;6:ra88. [PMID: 24106341 DOI: 10.1126/scisignal.2004512] [Cited by in Crossref: 112] [Cited by in F6Publishing: 109] [Article Influence: 14.0] [Reference Citation Analysis]
632 Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:468-473. [PMID: 22878240 DOI: 10.1097/mco.0b013e3283566614] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
633 Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014;111:447-52. [PMID: 25019921 DOI: 10.3238/arztebl.2014.0447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
634 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
635 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
636 Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 2011;26:517-22. [PMID: 21054523 DOI: 10.1111/j.1440-1746.2010.06567.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
637 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 152] [Article Influence: 40.3] [Reference Citation Analysis]
638 Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011;15:281-96, vii-x. [PMID: 21689613 DOI: 10.1016/j.cld.2011.03.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
639 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
640 Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol 2020;55:731-41. [PMID: 32451628 DOI: 10.1007/s00535-020-01686-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
641 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
642 Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H, Shimizu M. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci 2015;16:29207-18. [PMID: 26670228 DOI: 10.3390/ijms161226156] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
643 Chen SR, Qiu HC, Hu Y, Wang Y, Wang YT. Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. Phytother Res 2016;30:863-77. [PMID: 26879574 DOI: 10.1002/ptr.5594] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
644 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
645 Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, Chim AM, Chan AW, Choi PC, Woo J, Chu WC, Wong VW. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39:532-539. [PMID: 24417250 DOI: 10.1111/apt.12609] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 10.7] [Reference Citation Analysis]
646 Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109:589-597. [PMID: 24492753 DOI: 10.1038/ajg.2014.1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 16.7] [Reference Citation Analysis]
647 Matsui T, Hamada-Tsutsumi S, Naito Y, Nojima M, Iio E, Tamori A, Kubo S, Ide T, Kondo Y, Eguchi Y, Komori A, Morine Y, Shimada M, Utsunomiya T, Shirabe K, Kimura K, Hiasa Y, Chuaypen N, Tangkijvanich P, Naiki-Ito A, Takahashi S, Ochiya T, Tanaka Y. Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038612 DOI: 10.1111/hepr.13674] [Reference Citation Analysis]
648 Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 2013;48:1249-1258. [PMID: 23329365 DOI: 10.1007/s00535-012-0739-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
649 Bargellini I, Battaglia V, Bozzi E, Lauretti DL, Lorenzoni G, Bartolozzi C. Radiological diagnosis of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:137-48. [PMID: 27508183 DOI: 10.2147/JHC.S44379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
650 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 51.0] [Reference Citation Analysis]
651 Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:662-9. [PMID: 32971586 DOI: 10.3350/cmh.2020.0163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
652 Åberg F, Färkkilä M, Männistö V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcohol Clin Exp Res 2020;44:384-403. [DOI: 10.1111/acer.14271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
653 Flores YN, Auslander A, Crespi CM, Rodriguez M, Zhang ZF, Durazo F, Salmerón J. Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers. J Dig Dis 2016;17:304-12. [PMID: 26991251 DOI: 10.1111/1751-2980.12341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
654 Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HL, Sherman M, Hirschfield GM, Feld JJ. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology 2018;68:92-9. [DOI: 10.1016/j.jhep.2017.07.033] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 12.0] [Reference Citation Analysis]
655 Kimura T, Tanaka N, Tanaka E. What will happen in patients with advanced nonalcoholic fatty liver disease? Hepatobiliary Surg Nutr. 2019;8:283-285. [PMID: 31245415 DOI: 10.21037/hbsn.2019.01.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
656 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
657 Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018; 10(1): 41-50 [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
658 Morse CG. Fatty liver disease in HIV: common, underappreciated, and understudied. AIDS 2017;31:1633-5. [PMID: 28657965 DOI: 10.1097/QAD.0000000000001525] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
659 Yeh MM, Brunt EM. Pathological Features of Fatty Liver Disease. Gastroenterology 2014;147:754-64. [DOI: 10.1053/j.gastro.2014.07.056] [Cited by in Crossref: 184] [Cited by in F6Publishing: 162] [Article Influence: 26.3] [Reference Citation Analysis]
660 Altamirano J, Michelena J. Alcohol consumption as a cofactor for other liver diseases. Clin Liver Dis (Hoboken) 2013;2:72-5. [PMID: 30992828 DOI: 10.1002/cld.197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
661 Yuan L, Kardashian A, Sarkar M. NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities. Curr Hepatol Rep 2019;18:425-32. [PMID: 32523869 DOI: 10.1007/s11901-019-00495-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 35.5] [Reference Citation Analysis]
663 Vyhmeister R, Enestvedt CK. The Changing Liver Transplant Recipient: From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol. Clin Liver Dis 2021;25:137-55. [PMID: 33978575 DOI: 10.1016/j.cld.2020.08.012] [Reference Citation Analysis]
664 Xiong J, Wang J, Huang J, Sun W, Wang J, Chen D. Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: a ten-year retrospective study. Clinics (Sao Paulo) 2015;70:563-8. [PMID: 26247669 DOI: 10.6061/clinics/2015(08)06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
665 Linhart KB, Glassen K, Peccerella T, Waldherr R, Linhart H, Bartsch H, Seitz HK. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015;4:117-23. [PMID: 26005678 DOI: 10.3978/j.issn.2304-3881.2015.01.14] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
666 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
667 Cheuk-fung Yip T, Wai-sun Wong V, Lik-yuen Chan H, Tse Y, Pik-shan Kong A, Long-yan Lam K, Chung-yan Lui G, Lai-hung Wong G. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2018;16:765-773.e2. [DOI: 10.1016/j.cgh.2017.12.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
668 Suh B, Park S, Shin DW, Yun JM, Yang HK, Yu SJ, Shin CI, Kim JS, Ahn E, Lee H, Park JH, Cho B. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 2015;61:1261-1268. [PMID: 25502481 DOI: 10.1002/hep.27654] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
669 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 18.3] [Reference Citation Analysis]
670 Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491-503. [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
671 Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79. [PMID: 25921668 DOI: 10.1016/j.cld.2015.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 15.7] [Reference Citation Analysis]
672 Hwang KB, Kyaw YY, Kang HR, Seong MS, Cheong J. Mitochondrial dysfunction stimulates HBV gene expression through lipogenic transcription factor activation. Virus Res 2020;277:197842. [PMID: 31874211 DOI: 10.1016/j.virusres.2019.197842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
673 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 392] [Article Influence: 45.9] [Reference Citation Analysis]
674 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
675 Ahmed O, Liu L, Gayed A, Baadh A, Patel M, Tasse J, Turba U, Arslan B. The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. J Clin Exp Hepatol 2019;9:50-5. [PMID: 30765939 DOI: 10.1016/j.jceh.2018.02.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
676 George ES, Forsyth A, Itsiopoulos C, Nicoll AJ, Ryan M, Sood S, Roberts SK, Tierney AC. Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. Adv Nutr. 2018;9:30-40. [PMID: 29438460 DOI: 10.1093/advances/nmx007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
677 Lin YJ, Gao XM, Pan WW, Gao S, Yu ZZ, Xu P, Fan XP. A model to predict the onset of non-alcoholic fatty liver disease within 2 years in elderly adults. J Gastroenterol Hepatol 2017;32:1739-45. [PMID: 28183156 DOI: 10.1111/jgh.13760] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
678 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 142] [Article Influence: 17.3] [Reference Citation Analysis]
679 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: